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Due to repeated occurrence of serious, unexpected ADR over the years, lots of professionals 
and public attention has been drawn to ADRs, and this has led to more focused attention on 
drug safety surveillance system. ADR incidence is associated with high rate of morbidity and 
mortality and this incidence cut across all age groups with a large number of hospitalisation, 
and huge financial burden on Nigeria healthcare system and the society. Unfortunately, the 
assessment, monitoring, and reporting system of ADR in Nigeria healthcare system still have 
lots of room for improvements, especially with the involvement of tertiary hospitals in Nigeria. 
Due to the above-stated problems, the assessment and analysis of ADR are critical to promptly 
detect the likely safety and security issues that might be associated with medicinal products; 
hence this research aims to analyse assessment and reporting of ADR in Tertiary Hospitals in 
Lagos State, South-West Nigeria”. 
The purpose of this research is to identify bottlenecks and loopholes in the system that hinders 
effective ADR practice in tertiary hospitals in Lagos state Nigeria. The research involved major 
stakeholder of pharmacovigilance activities which includes; HCPs (Doctors, Nurses, and 
pharmacists) and patients of tertiary hospitals. It aims to interact with HCPs to determine their 
perception towards direct patient reporting of ADR. Also patients were considered in the study 
to determine their level of awareness/knowledge towards ADR reporting. 
The primary data was collected using an online survey and phone interview. The survey was 
targeted at 450 participants, and a total of 405 respondents were obtained in return in which 
270 were patients, and 135 were HCPs (doctors, nurses, and pharmacists) recording a response 
rate of 90%.  For the interview, 12 people were scheduled to be interviewed but 6 responses 
were obtained in which 2 were doctors, 2 were nurses, and 2 were pharmacist recording a 
response rate of (50%). 
From the analysis conducted a significant number of the HCPs participants have basic 
understanding of ADR but have no knowledge of causality assessment and they established 
that they are not sufficiently trained on how to assess and report ADR. Several bottlenecks such 
as lack of knowledge/awareness, lack of feedback from NPC, unavailability of ADR reporting 
forms, insufficient staffs, cumbersome procedures, and excessive workload were established 
as most challenging issues. However, a highly significant number 92% are willing to update 
their knowledge on ADR practice and opted to make it a mandatory obligation to help resolve 
underreporting issues faced by the country. 
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A significant number of Patients participants established they are not familiar with ADR and 
the importance of reporting, while the HCPs also acknowledge that they are not aware that 
patients can report ADR directly neither do they think it is a good idea because they are of the 
perception that patients can’t generate a valid/quality ADR reports. 
Creating more awareness for both HCPs and general public, organising frequent training, 
workshop and seminars to update the knowledge of HCPs, providing adequate resources, 
incorporating ADR module into the curriculum of HCPs both during their undergraduate and 
orientation program when newly employed, establishing an active pharmacovigilance centres 
in tertiary hospitals to help monitor and guide ADR practice, educating and encouraging 
patients on ADR reporting and it is importance, are sustainable recommendations that will 
improve ADR practice and contribute invariable to pharmacovigilance system in Nigeria. 
Key Words: Pharmacovigilance, Adverse Drug Reactions (ADRs): awareness, knowledge, 
challenges, causality assessment, ADR assessment and reporting, Direct patient reporting, 
Healthcare Professionals (HCPs), Nigerian Agency for Food and Drug Administration and 
Control (NAFDAC), National Pharmacovigilance Centre (NPC), SMS code, ADR forms/yellow 
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CHAPTER 1: INTRODUCTION 
1.1 Overview of the Study 
Medicinal products are expected to save lives and maintain public health as “dying from a 
disease is sometimes unavoidable; dying from medicine is unacceptable” (Noll, 2016). They 
are vital components of patient management and the healthcare system which helps in the 
allayment, management, and prevention of diseases. 
Before the release of medicinal products to the market, they undergo various phases of clinical 
trials (Phase I-III) alongside strict regulatory guidelines and standards to ensure the medicinal 
products are of optimum quality, safety, and efficacy. However, during the trials, products are 
only tested on a limited sample size of patients with stated eligibility criteria, limited time, and 
used under the pre-decided protocol. These stated conditions make it impossible to detect long-
term effects of drugs and their interactions, and rare ADR (ADRs) since the real world is not 
bounded by these protocols and conditions applicable to clinical trials. Also, drug safety 
information that is available after a drug has been approved, licensed, and released to the 
market is usually limited since the sample size of the patient involved in the clinical trial is 
small when compared to the real-world population of patients that requires the prescription of 
these drugs. Therefore, Post-marketing surveillance (phase-IV) which marks the 
commencement of pharmacovigilance activities is essential to detect and report all these 
adverse events and other drug-related issues that were previously not detected during the pre-
marketing studies (Mishra and Dhikav, 2016).  
                          Figure 1: Phases of Clinical Trials sourced from (St. Luke’s, 2020). 
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Evaluation and Monitoring of ADR 
Monitoring of ADR through pharmacovigilance is essential to patient safety, and to ensure a 
good quality of human life and reduce the impact of ADRs on patients, as it is well known that 
no drug is free form adverse effects, therefore the need for continuous monitoring of drug and 
it is safety was introduced. According to World Health Organization (WHO, 2020), 
Pharmacovigilance can be defined as the “science and activities relating to the detection, 
assessment, understanding, and prevention of adverse reactions or any other medicinal 
products related issues” (WHO, 2020). The need for pharmacovigilance activities cannot be 
overemphasized as it helps in early detection of ADRs and identification of risk factors. It 
contributes significantly to the protection and sustenance of public health by promoting safe 
and effective use of medicinal products. The fundamental concept is to detect and prevent ADR 
in humans which may occur due to the usage of medicinal products before or after marketing 
authorization conditions (Nour and Plourde, 2019).  
Assessment and spontaneous reporting of ADRs are vital methods for identifying new potential 
issues that are drug-related, and it is estimated that only about 6-10% of ARDs are reported 
which makes underreporting a major obstacle.  Pharmacovigilance also aims to precisely 
optimize and identify medicinal products’ benefit/risk ratio, effectiveness, and harm all through 
is life cycle, starting from discovery stage to post-marketing surveillance, and the mechanism 
underlying the ADR. The concepts of pharmacovigilance are dependent on these three pillars; 
1. New information should be regularly obtained from reliable scientific resources such 
as HCPs, patients, market authorization holders, international/public agencies, etc. 
2. Classification and assessment of the obtained information 
3. The contents of the information and all actions taken will be circulated to all health 
sectors (Yadav, 2008). 
The four elements that complete assessment and reporting of ADRs include- the drug, patient, 
an adverse reaction, and the reporter (HCPs). HCPs play a vital role in the pharmacovigilance 
system especially for early recognitions, detection, assessment, reporting, and management of 
ADRs. Therefore, they require considerable knowledge and expertise in the field of medication 
safety, which is why it is essential to improve the knowledge, attitude, involvement, and 
practices of HCPs towards ADR reporting and pharmacovigilance to address various 
challenges impacting maximum ADR reporting rate and optimum pharmacovigilance 
structure. Also, they are expected to consider ADR reporting as their professional obligation to 
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achieve an effecting reporting system which is paramount to improving patient safety and their 
overall health. 
Similarly, the role of patients in reporting suspected ADRs can help add value and improve the 
efficiency of pharmacovigilance system. Patients should be encouraged to actively participate 
in the reporting system as they can describe their reactions in more details and the effect on 
their lives. They can help to generate new potential signals and provide useful information on 
likely causality, which will help bridge the gap of underreporting (Adisa and Omitogun, 2019). 
 
           Figure 2: Monitoring system of ADR sourced from (Yadav, 2008). 
Causality Assessment of ADR 
ADRs signals are reported information on potential causal relationships between a drug and an 
adverse event. There are several terms related to pharmacovigilance and this includes adverse 
events, ADR, and medication errors.  
Adverse Event (AE) can be described as any harm that happens to patients during the use of a 
drug or other therapy, and the cause may not be directly related to the medicinal product or 
therapy being given.  
Adverse Drug Reactions (ADRs) as defined by WHO is “response to a drug that is noxious 
and unintended and occurs at doses normally in man for prophylaxis, diagnosis or disease 
therapy, or for the modification of physiological function” (WHO, 2019). They are global 
problems of major concern that contribute to the high rate of morbidity and mortality across all 
age groups, and they also impose a major impact on the already strained healthcare system, and 
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substantial financial burden on society which greatly influences public health. Patients that are 
hospitalized due to ADRs incidence is estimated to be around 24.1%, and studies indicate that 
the death rate of patients who encounter ADRs is about 19.18% higher, and the duration of 
hospital stay is 8.25 % higher. It is often difficult to decide if an adverse clinical event is an 
ADR or it is due to the deterioration in a patient health condition, therefore a causality 
assessment is done to determine the causal relationship between the drug and their adverse 
reaction, to minimize the suffering of patients with ADRs (Gaurav Chhabra, 2017). 
Causality Assessment is an integral part of ADR reporting and a common routine procedure in 
pharmacovigilance, it is performed to evaluate the relationship between particular drug 
treatment and the occurrence of an observed adverse event. It helps in signal detection of 
unusual and unexpected ADRs that were previously undetected during clinical trial evaluation 
of a drug. Also, it helps to better evaluate the benefit/risk of a drug profile to prevent future 
recurrence, while also helping the regulatory bodies to evaluate received ADRs report. There 
is a need for HCPs to be conversant with structured tools devised for causality assessment of 
suspected ADRs, and some methods to assess ADRs include: 
▪ Clinical Judgement: This is usually performed by expert/HCPs by evaluating the ADR 
based on their knowledge and experience about the ADR. 
▪ Probabilistic Approach: This method enables simultaneous assessment of multiple 
causes of ADRs, and the causality assessment is based on the study of prior and 
posterior probability. 
▪ Algorithms: They are used to derive a structured and harmonized ADR assessment by 
classifying uncertainty in a semi-quantitative way to get the likelihood of causality. 
Naranjo algorithm and World Health Organization-Uppsala Monitoring Centre (WHO-
UMC) are the most commonly used algorithm to assess ADR in this case. 
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             Figure 3: WHO causality assessment criteria sourced from (Gaurav Chhabra, 2017) 
ADR can either be; 
o Serious Adverse Reaction (SAR): This is when the reaction to the drug is serious and 
requires the patient to be hospitalized. It can be life-threatening, leading to disability, 
or even death. 
o Unexpected Adverse Reaction (UAR): This is when the reported or detected reaction 
has not been previously stated in the medicinal product information or it is 
unpredictable with drug characteristics. 
o Suspected Unexpected Serious Adverse Reactions (SUSAR). This majorly is a new 
side effect, it is when the reaction is serious and it is unexpected. 
Over the years, ADRs are mainly classified as type A (dose-related) and type B (non-dose-
related) reactions but other categories were added to the list over the subsequent years based 
on research conducted. 
14 
 
▪ Type A (Augmented): These are dose-related reactions and are usually related to the 
principal action of the medicinal product either through normal dose or overdose. They 
are common and mainly predictable from the known pharmacology of the medicinal 
product and skilled management can help reduce their incidence. It has both toxic and 
side effects and associated examples of this category include anticholinergic effects of 
tricyclics, digoxin toxicity, hypoglycaemia-insulin. 
▪ Type B (Bizarre): These are non-dose-related reactions and are not related to the normal 
pharmacology of the medicinal product. They are less common, and any exposure is 
sufficient to trigger this type of reaction, also they are usually unpredictable, severe and 
might likely result in serious morbidity or even mortality. Associated examples of this 
category include anaphylaxis reactions, idiosyncratic reactions, and drug allergy. 
▪ Type C (Chronic): These are dose and time-related reactions, they occur due to dose 
accumulation or long-term use of medicinal products and they are usually chronic. 
Associated examples of this category include Cushing syndrome from the use of 
corticosteroids for adrenal suppression, analgesic neuropathy, 
▪ Type D (Delayed): These are time-related reactions in which drug does not accumulate 
but reactions manifest due to long-term use of medicinal product. Associated examples 
of this category include teratogenicity and carcinogenicity effects like tardive 
dyskinesia which occurs after a long period of using typical antipsychotics. 
▪ Type E (End of Dose): These are withdrawal reactions that result from undesired 
effects of ending drug usage. Examples of this category include syndrome from opiate 
withdrawal and rebound hypertension after discontinuing usage of clonidine. 
▪ Type F (Failure of Therapy): These reactions are used to illustrate undesirable 
reduction or increase in medicinal product efficacy. It occurs as a result of an 
unexpected failure of therapy in which a drug efficacy increases or decreases 
undesirably. Associated examples of this category include patient resistance to 
antibiotics which might lead to decreased effect of the drug, effects of critical ailment 








TYPE TERM CHARACTERISTIC EXAMPLES 
A Augmented Dose-dependent, Frequent, 
Predictable, related to the 
pharmacological effect of the 
drug. 
Hypoglycaemia-insulin, bleeding 
after anticoagulants, Digoxin 
toxicity. 





C Chronic Dose and time-dependent, 
Prolong toxicity exposure 
Analgesic neuropathy, Cushing 
syndrome from cortisone. 
D Delayed Time-dependent Carcinogenesis, Teratogenesis, 
chronic organ damage. 
E End of Dose Time-dependent, Relapse 
after the withdrawal of 
therapy. 
Rebound or Relapse phenomena 
due to withdrawal effects of drugs 
i.e. Opioids or antiepileptic. 
F Failure of Therapy Dose-related, Common, 
mostly occur due to drug 
interactions. 
Inadequate dosage of an oral 
contraceptive, 
            Table 1: Classification of ADRs adapted by the author from (Edwards and Aronson, 2000). 
Pharmaceutical Regulatory Affairs 
Medicinal product regulations are the blend of legal, regulatory, and technical measures that 
are taken by assigned authorities/agencies to ensure the safety, efficacy, and quality of 
medicines, and also the pertinence, precision of the product details. It is of utmost importance 
to regulate pharmaceutical products in order to develop safe, quality, and effective medicinal 
products (Pierre-Louis Lezotre MS, 2014). 
Pharmaceutical regulatory agencies play a vital role in the industry by ensuring the drug 
development process meets all applicable legal requirements to ensure the safety, quality, and 
efficacy of medicinal products available to the public. They aim to protect and improve public 
health and minimize accidents in the medical world by ensuring a great level of proficiency 
and control assessment is maintained, and preventing the penetration of counterfeit, harmful, 
and substandard products into the market. Also, they provide the strategic, tactical, and 
operational direction needed to promote the development and delivery of safe, quality, and 
effective medicinal products. Their functions and tasks range across all aspects of the industry 
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such as drug research and development, product registration, price control, manufacturing, 
marketing, distribution, and intellectual property protection. Furthermore, they implement and 
enforce laid down pharmaceutical regulations, guidelines required for medicinal product 
development, licensing, marketing, and labelling. Examples of the various regulatory agency 
in each country include; US Food and Drug Administration (FDA), European Medicines 
Agency (EMA) for Europe, Health Canada,  Health Products Regulatory Authority (HPRA) 
for Ireland, Medicines and Healthcare Products Regulatory Agency (MHRA) for the UK, and 
National Agency for Food and Drug Administration and Control (NAFDAC) for Nigeria, etc. 
(Sengar and Tripathy, 2011).  
National Agency for Food and Drug Administration and Control (NAFDAC) is a federal 
regulatory agency in Nigeria responsible for all medicinal products related affairs. It was 
established in January 1993 under a military decree which has now been amended during the 
democratic system to Act Cap N1 Laws of the Federation of Nigeria (LFN) in 2004 in order to 
control and regulate the manufacture, importation, exportation, advertisement, sale, 
distribution and use of drugs, medical devices, foods, cosmetics, chemicals, and all packaged 
water/drinks (NAFDAC, 2017). The national data bank of all reported ADRs in the country is 
coordinated by the National Pharmacovigilance Centre (NPC) which is a domicile in 
NAFDAC. There have been severe ADRs in Nigeria which has contributed to the high 
mortality and morbidity rate in the country and this include; error in the formulation of My 
Pikin teething powder which led to the death of 150 children, and the incidence of toxic 
paracetamol in 2008 which was adulterated with diethylene glycol and claimed the lives of 
some infants and young children.  To reduce the burden of ADRs in Nigeria, NAFDAC has 
incorporated several measures to improve the quality of drug safety surveillance systems in 
Nigeria and ensure the efficacy, safety, and quality of all medicinal products.  
Although Nigeria is currently participating in the WHO Uppsala monitoring program but their 
contribution towards the database is not up to the stated target and this can be attributed to lack 







Nigeria Healthcare System 
The Nigeria healthcare system is divided into three levels namely- primary, secondary, and 
tertiary. The term tertiary is used to classify facilities owned by tertiary institutions or specialist 
centres that provide a full complement of medical services and medical care that requires highly 
specialized support functions, skills, and technology, usually for patients with uncommon, 
complex or rare severe medical conditions. They also serve as a referral centre for both primary 
and secondary centres, and they can be categorized into 3 different types which are: 
▪ The Tertiary Institutions Teaching Hospitals- This category provides the underlying 
structure and teaching to HCPs during their undergraduate and postgraduate studies, it 
is also the best-suited category for research and healthcare services. The state of this 
research has most of the efficient teaching hospitals in the country which include- 
Lagos State University Teaching Hospital (LASUTH), Lagos University Teaching 
Hospital (LUTH). 
▪ The Federal Medical Centre: This category provides healthcare services and residency 
training. 
▪ The Specialist Hospitals: This category provides healthcare services in focused areas 
that are of public health importance, examples of this category in Lagos state include; 
orthopaedic hospitals (National Orthopaedic Hospital Igbobi), neuro-psychiatric 
hospitals (Federal Neuro-Psychiatric Hospital Yaba), St. Nicholas Hospital, Eko  
Hospital, Havana Specialist Hospital, etc. 
Statement of Problem 
Due to morbidity and mortality rate associated with ADR from the usage of medicinal products 
in Nigeria, the country needs to have a deep-rooted system for pharmacovigilance activities.  
The incidence of ADRs cut across all age groups with a large number of hospitalizations, as 
well as a high substantial financial burden on Nigeria society and it is healthcare system. 
Several cases such as Steven-Johnson syndrome, Nicolau syndrome due to dipyrone usage, the 
diethylene glycol incident from my pikin teething powder has negatively impacted public 
health (Olowofela et al., 2016). It is estimated that only about 6-10% of ADRs are reported in 
Nigeria and several factors including slow involvement of tertiary hospitals, lack of awareness 
and knowledge of the reporting system and pharmacovigilance activity are stated to be a key 
factor. Also, the involvement of HCPs in the country is still quite laid back as most of them do 
not report a large proportion of the ADRs and this resulted in underreporting which is a crucial 
obstacle to spontaneous reporting of ADRs and poses a huge challenge to pharmacovigilance 
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activity. Nigeria lacks considerable knowledge and expertise in the pharmacovigilance field 
especially for early recognition, detection, reporting, and management of ADRs and this poses 
a great challenge to patient health and safety. Furthermore, lack of active patient involvement 
in the reporting system contributes to the underreporting as patients are major stakeholders in 
achieving spontaneous ADRs reporting which is a global phenomenon and the cornerstone of 
pharmacovigilance activity, therefore their impact needs to be evaluated and strengthened  
(Adisa and Omitogun, 2019). 
Research Purpose 
ADR present risk to patients' lives as they could significantly impact their lives by causing 
disability and mortality, and even cause an economic drain on healthcare system. A group of 
scientist once proposed that assessment of ADRs is likely the most essential part of drug 
therapy, and it helps in the identification of early signals related to the use of medicinal product, 
hence; active involvement of reporters contributes greatly to the success or failure of any 
spontaneous reporting system (Awodele et al., 2018). This research is designed to explore how 
HCPs assess ADRs in tertiary hospitals. Also, this research will cover the passive surveillance 
method of pharmacovigilance which involves the spontaneous reporting of ADRs. It is a 
voluntary communication from HCPs or patients to regulatory bodies or the company that 
manufactures the medicinal product to help enhance post-marketing safety signals through 
identification, assessment, and reporting of ADRs. To effectively figure out and address the 
root cause of poor ADR reporting and suggest possible ways of improving pharmacovigilance 
structure in the aforementioned hospitals, this research will focus on tackling the slow 
involvement of tertiary hospitals in pharmacovigilance activities, and possible ways to impart 
knowledge regarding pharmacovigilance to HCPs, hence this research is designed to evaluate 
the following: 
▪ Analyse the assessment and reporting process of ADR in tertiary hospitals in Lagos 
State, Nigeria. 
▪ The impact of patients in reporting ADRs, and the attitude, perception of HCPs towards 
patient reporting ADRs in tertiary hospitals in Lagos State Nigeria. 
Significance and Justification of the Study 
The overall goal of this research is to analyse the assessment and reporting process of ADRs 
in tertiary hospitals in Lagos state, to figure out reasons for their slow involvement in 
pharmacovigilance activities. The previous research conducted on the pharmacovigilance 
system in Nigeria has been mainly focused on south-south and eastern healthcare system in the 
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country or been generalized, and their outcome shows several challenges and the need for 
improvement. Reviewed literature shows that extensive research has not been conducted in the 
involvement of tertiary hospitals, and the evaluation of the assessment of ADRs reported by 
HCPs in these hospitals. Furthermore, patients are a major stakeholder in fulfilling 
pharmacovigilance activities and spontaneous ADR reporting, but most research conducted has 
been majorly focused on HCPs and neglect the patients experiencing the ADRs; hence this 
study will also analyse the involvements and knowledge of patients in ADR reporting system. 
This research aims to recommend possible ways that can lead to spontaneous reporting 
improvement to fully integrate and maintain pharmacovigilance in the healthcare system.   
This study will invariably contribute to the overall pharmacovigilance structure in place in 
tertiary hospitals by giving sustainable recommendations that will benefit both the hospitals 
and HCPs by increasing their awareness, help them identify and address the gap in the reporting 
system.  
Aims and Objectives of the Research 
The aims and objectives of this research are outlined below: 
1) To assess the knowledge, attitude, and practice of HCPs towards Pharmacovigilance 
and ADR in tertiary hospitals in Lagos State, south-west Nigeria. 
2) To elicit the experience of patients regarding reporting of ADRs and evaluate it is 
impact on pharmacovigilance structure. 
3) To make sustainable recommendations towards patients reporting ADRs in Lagos state 
tertiary hospitals, which invariably will contribute to the overall pharmacovigilance 
system in place in the hospitals. 
Research Questions 
1. What are the assessment and reporting methods used by HCPs to identify and report 
ADRs in Lagos State tertiary hospitals? 
2. What are the perceptions of HCPs towards patient reporting ADRs in Lagos State 
tertiary hospitals? 
3. What is the level of awareness and knowledge of ADR among patients in Lagos state 
tertiary hospitals? 
4. What are the challenges impacting ADR assessment, and responsible for the slow 






H0: There is no significant association between awareness of ADR and the identification of 
ADR. 
H1: There is a significant association between awareness of ADR and the identification of 
ADR. 
Hypothesis Two- 
H0: There is no significant association between patients’ source of knowledge on ADR and 
their ability to identify and report any experienced ADR. 
H1: There is a significant association between patients’ source of knowledge on ADR and their 
ability to identify and report any experienced ADR. 
Hypothesis Three- 
H0: Perception of HCPs has no impact on direct patient reporting of ADR in Lagos state tertiary 
hospitals. 
H1: Perception of HCPs has an impact on direct patient reporting of ADR in Lagos state tertiary 
hospitals. 
Scope of the Study 
This dissertation will run across the assessment and reporting of ADRs in Nigeria and will 
focus mainly on HCPs and patients in Lagos state tertiary hospitals. 
Structure of the Study 
This dissertation is divided into five main sections which are introduction, literature review, 
research methodology, presentations and analysis of findings, and conclusions & 
recommendations. The first chapter begins with an introduction of research subject topic, it 
includes several subheadings such as; an overview of pharmacovigilance activities and ADRs, 
purpose of this research, significance and justification of research, and the aims and objectives 
of this research. 
The second chapter which is the literature review presents the critical review of published 
research on pharmacovigilance activity, ADRs reporting system, healthcare professional 
involvement, and challenges that impact spontaneous ADRs reporting systems both in Nigeria 
and other parts of the world. Furthermore, it contains the conceptual framework which shows 
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the various elements and sub-elements that describe the concepts of assessment and reporting 
of ADRs. 
The third chapter which is the research methodology includes strategy and design used to 
conduct this research. It discusses the methodological approach that the author has taken to 
meet her research goals and tackle her research questions. It also discusses her method of data 
collection which includes a mixed method of qualitative approach using phone interviews and 
a quantitative approach using questionnaires. Also, an Interpretivism and positivism research 
philosophy is used in this research alongside a deductive approach. 
The fourth chapter which is the presentation and analysis of findings discovered, it discusses 
the data collected from both the interviews and questionnaire. Additionally, it interprets and 
explains the findings discovered as well as their impacts on research aims and objectives.  
The fifth part which is the recommendations and conclusions discusses the summary and 
interpretation of the findings. It includes contributions and limitations of the research, 
recommendations for future research, practice recommendations. Furthermore, a final 
conclusion is drawn, and this relates all the information contained in the previous chapter and 
illustrates clearly how the research aims and objectives have been met.  
Conclusion: 
An analysis to evaluate the assessment of ADRs by HCPs and the impact of patients in the 
reporting system will invariably contribute to the overall pharmacovigilance structure in place 
in tertiary hospitals. It will provide a better insight into the loopholes and the various challenges 
encountered by HCPs in achieving spontaneous ADRs reporting. Furthermore, other measures 
such as adequate support and resources from applicable regulatory agency, increase awareness 
and visual displays of ADR reporting guidelines will serve as a constant reminder which will 
help lessen the burden of ADRs impact on patients’ lives and the economy, and also improve 








CHAPTER 2: LITERATURE REVIEW 
2.1. Global Perspective 
Medicinal products are the most common medical interventions primarily used in the treatment 
and control of diseases to relieve patient’s suffering. But drugs have also been long recognized 
to prove fatal despite is medical intervention. Just as the popular saying that “Drugs are 
double-edged weapons” since they are likely to produce ADR from time to time (Shamna et 
al., 2014). ADR are global health problem that requires the attention of all stakeholders 
regardless of the settings since it is a major limitation in providing adequate healthcare to 
patients at global level. Medicinal product usage differs after they are released to the market as 
compared to during their evaluation at the preapproval stages because they are used by a larger 
heterogeneous population. Hence, the establishment of an international drug monitoring 
program by WHO to create an active surveillance system to help monitor the safety of drugs 
and remove harmful drugs from the market (Shamna et al., 2014). 
The safety profile of medicinal products is dynamic, thus new information is continually 
assessed regarding it uses and outcomes through post-marketing surveillance. Post-marketing 
surveillance provides data that enhance the rational and safe use of a medicinal product, and 
out of the various methods involved in achieving it, national voluntary reporting systems are 
the most essential channel used for collecting and assessing information related to drugs 
adverse events. Pharmacovigilance is becoming a scientific discipline in it is own right since it 
plays a vital role in pharmacotherapeutic decision making, be it at the international, national, 
regional, or individual level (Yadav, 2008). Each country has it is specific coordinating 
pharmacovigilance program/unit that is responsible for gathering voluntary reports from HCPs 
and patients as regards ADR and other medicinal product-related errors. This program enables 
confidential reports of drug incidents and ADR needed for the provision of information to the 
public health community to optimize patient safety and to analyse data to detect potential issues 
and trends (Yadav, 2008). 
Globally, the success of any pharmacovigilance system is based on several factors which 
include; adequate public awareness on the need to report suspected ADRs, viably trained HCPs, 
active communication system between regulatory agencies and public, fund, resources, and 
support from the government, Equipped quality control laboratories, Free flow of information 
such as feedback and inquires (Olowofela, 2018). As more drugs are produced and marketed, 




2.2. Overview of Pharmacovigilance in Nigeria 
World Health Organization (WHO) opined that Nigeria- located in the western region of 
Africa, and made up of 36 states including it is federal capital territory Abuja- is a developing 
African country and it is categorized as a lower-middle-income country (World Bank Group, 
2020). It is a highly populated country with a current population of over 204 million people as 
stated by the world population statistics (Population Stat, 2020b) and has a diverse ethnic 
group.  
According to WHO, it is estimated that the average life expectancy of a Nigerian is around 
54.5 years of age, and this can be attributed to several tragic and striking health issues being 
faced in the country which also contributes to it is high mortality rates. Additionally, Nigeria 
has an infant mortality rate of 54.7% per 1000 live births, and it is approximated that out of 
every five children birthed in Nigeria, one is expected to die before clocking age five due to 
numerous health burden, risk, and issues faced by the country healthcare system. However, the 
country has been projected to have over 401 million populated by 2050 despite the death rate, 
and this is because Nigeria has a faster population growth rate of 2.6% which is significantly 
higher than other countries with the same size (Worldometer, 2020). 
The journey of improving drug safety in Nigeria started in the 1980s with the involvement of 
is ministry of health by sponsoring some of their staff for training at the Uppsala Monitoring 
Centre. A major advancement in the history of pharmacovigilance in the country commenced 
in a tertiary hospital called University of Benin Teaching Hospital (UBTH) in the late 80s and 
early 90s when they set up an adverse reaction monitoring unit, established ADR registry, and 
drug/poison information centre (Olowofela et al., 2016). Furthermore, the unit created a 
reporting system that generated sufficient spontaneous ADRs reports which facilitate the 
launch of the National Pharmacovigilance Centre (NPC) in 2003, and Nigeria admission into 
the WHO Program for International Drug Monitoring Programme (PIDM) in 2004 as the 74th 
member country of the program. This launched a new era for pharmacovigilance activity in the 
country (Opadeyi et al., 2018).  The country has sustained is activity through training it HCPs, 
general awareness and sensitization campaigns using electronic media and print about drug 
safety, and also the initiation of electronic devices to curtail falsified medicines and 
substandard drug products which is a major contribution to ADRs in the country. 
Pharmacovigilance growth in Nigeria has been propelled by several factors which include the 
establishment of NAFDAC in 2004, and the formulation of the Nigerian National Drug policy 
in 2005 which was further clarified in 2012 by the establishment of the Nigerian 
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pharmacovigilance policy document which strongly positioned drug safety in national 
discussion (Federal Ministry of Health, 2012). 
2.3. Nigeria Pharmacovigilance Approach and Governance Framework 
The National Pharmacovigilance Program in Nigeria was established with the objectives of 
monitoring the safety of medicinal products and creating an adverse reaction database for the 
Nigerian population. Nigeria has been mainly focused on ADR, counterfeit/falsified medicinal 
products, although the activity of monitoring and reporting ADR in the country is still in it is 
infancy (Opadeyi et al., 2018). 
According to Olowofela (2016), Nigeria has several tragic health and drugs related issues due 
to the burden of communicable and non-communicable diseases, poor recognition and 
quantification of morbidity and mortality rate associated with ADRs from using medicinal 
products. To establish a viable pharmacovigilance system in the country, NAFDAC's first step 
was the introduction of yellow forms in 2004 to help in early discovery and reporting of ADRs 
and to quantitatively evaluate the aspects of information dissemination and risk-benefit analysis 
essential for drug improvement. The five major components of the form include; patient’s 
details, ADRs details, suspected drug details, concomitant details, and sources of reports 
(Awodele et al., 2018). 
Pharmacovigilance activities in Nigeria are coordinated at NAFDAC headquarters in Abuja by 
the National Pharmacovigilance Centre (NPC) which is a department of NAFDAC. Also, 
National Drug Safety and Advisory Committee (NDSAC) which consists of pharmaceutical 
and medical experts in the related field was inaugurated in 2006 to help provide expert advice 
on pharmacovigilance relevant issues. In 2012, the pharmacovigilance unit was separated from 
the Food and Drug Information Centre (FDIC) and upgraded to an independent directorate to 
manage all pharmacovigilance activities including post-marketing surveillance. Furthermore, 
zonal centres in six geopolitical zones in the country were established in 2013 based on WHO 
regional centres advocates, as these centres are an effective way to help facilitate the reporting 
system and enhance pharmacovigilance activities all over the country.  Nigeria's objectives of 
establishing the zonal centres were to decentralize NPC activities and monitor the progress of 
pharmacovigilance activities at the institutional level. The zonal centres help to support 
capacity building and training for pharmacovigilance in the areas of their jurisdiction, help 
facilitate dissemination of information to patients and HCPs from the national centre, 
distribution of ADR forms and collection and evaluation of Individual Case Safety Reports 
(ICSRs) from reporters, and also acknowledgments and feedback conveyance to reporters. 
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NPC also works alongside several academic institutions and marketing authorization holders 
(MAH) which all have significant roles and contributions towards the development of drug 
safety in Nigeria in accordance with the developed pharmacovigilance policy (Olowofela, 
2018).  
Since NPC establishment in the country, it serves as a repository for reported ADRs and also 
liaise with applicable international organizations on pharmacovigilance activities such as 
World Health Organizations, European Medicines Agency (EMA), and US Food and Drug 
Administration (USFDA). The NPC centre in Abuja is responsible for collating, processing, 
evaluating, and handling ADRs reports in the country, the reports are evaluated and verified 
according to WHO criteria before they are sent to WHO Uppsala monitoring centre using 
VigiFlow software and stored in VigiBase data system. NPC actively promotes and focuses 
greatly on the necessary steps required to transform and implement an ideal framework to fulfil 
ADR obligations. Guidance documents and reporting forms were established by NPC to 
promote an efficient reporting system among Market Authorization Holders (MAH) and HCPs 
in the country. Furthermore, they created a reporting Pharmacovigilance Rapid Alert System 
for Consumer Reporting (PRASCOR) to encourage patient’s contributions towards 
pharmacovigilance reporting system in Nigeria, this utilizes text messages to report ADRs 
directly to the NPC for evaluation. All the measures put in place are to increase awareness 
about pharmacovigilance, bring a centre closer to the practice of reporters, and instil a sense of 





Figure 4: Pharmacovigilance operating system in Nigeria, sourced from (Olowofela et al., 2016) 
2.4 Pharmacovigilance Activity and ADR Reporting 
Pharmacovigilance activity is an essential part of drug therapy which helps in detection, 
monitoring, identification of risk factors, designing strategies to help reduce ADRs occurrence, 
and dissemination information. The scope of pharmacovigilance is wide with increasing 
product concerns, and it is not only limited to drugs but has now been expanded to other 
products such as medical devices, biologics, vaccines, blood products, and herbal products 
(Yadav, 2008). Pharmacovigilance involves actions to detect and assess ADR, and evaluation 
of the probability of the association within the drugs and the ADRs. It includes the consistent 
monitoring of drug safety and reporting of ADR of medicinal products that are already 
available in the market, most especially during post-marketing surveillance. These surveillance 
activities are very essential to enable the early detection of unexpected and/or serious ADR and 
assure the safe use of drugs. Pharmacovigilance is the principal unit control of the menace of 
ADR, and it importance in therapy outcome is essential and crucial for effective clinical 
practice and public health science (Oreagba et al., 2011). In particular, Pharmacovigilance 
effectiveness and success are directly dependent on the involvement of HCPs and patients 
(according to new European Pharmacovigilance Legislation) through their prompt and frequent 
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reporting of suspected ADR as under-reporting can have a negative impact and disadvantages 
(Palleria et al., 2013). 
A study by (Kaur et al., 2019), titled pharmacovigilance study of ADR in a tertiary care hospital 
in Haryana retrospectively analysed a total of 233 ADRs reports from various department of 
the hospital. The authors established that more ADRs were noted in females which is 133 
making about 53% of the patients studied, and 100 was noted in males which is about 43% of 
the patient studied. Furthermore, the authors established that the highest reported ADRs were 
from the dermatology department with a case of 60 making 25.8%, followed closely by the 
surgery department with a case of 54 making 23.2%.  Several organ systems were affected by 
ADRs and this includes- The skin which was the maximally affected area noted 154 making 
about 70%. Followed by the gastrointestinal system which noted 28 making about 13%, and 
the other organ system such as the central nervous system, immunological, endocrine, 
respiratory, and cardiovascular make up the remaining 17% (Kaur et al., 2019). 
 
           Figure 5: Organ system involvement due to ADRs, sourced from (Kaur et al., 2019) 
2.4.1. Current State of ADR in Nigeria 
Global drug safety greatly depends on a strong national system that monitors the development 
and quality of medicinal products, assesses and reports their harmful effects, and provides 
accurate information for their safe use (Palleria et al., 2013). Medicinal product usage, patterns, 
and the nature of common diseases, disease burden, and cultural norms that can influence the 
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assessment and reporting of ADR are unequally distributed among high and low-income 
countries. It has been established that developed countries use more drugs and they have greater 
resources in terms of infrastructure, money, and competency to survey the safety of medicinal 
products. Aagaard et al. stated that there is extensive information about ADRs occurrence in 
high-income countries especially from USA and Europe, but there has been only limited data 
about ADRs occurring in low-income countries. However, the safety of medicinal products at 
a global level needs more information and it is essential to determine if the occurrence of 
reported ADRs is associated with national wealth (Aagaard et al., 2012). A study that analysed 
ADRs reported to WHO VigiBase for antimalarial medications established high reporting rates 
from high-income countries than low-income countries despite the huge malaria cases in low-
income countries. There were wide variations in reporting rates between country income level 
and this can be attributed to the fact that high-income countries have a well-established and 
long-term pharmacovigilance system and resources (Aagaard et al., 2012).  
There have been significant literature reviews of ADRs observed in Nigeria populations due to 
drug quality issues, polypharmacy, high usage of herbal medicines, free medicines given at 
public-health programs, and this has been reported to contribute to the rate of ADRs in the 
country (Olowofela et al., 2016). According to a survey carried out on the Nigerian market, the 
survey revealed that about 48% of the drug tested did not conform to international 
pharmacopeia standards. This incident led Nigeria pharmacovigilance activity to be majorly 
focused on ADRs as well as SSFFC (Olowofela et al., 2016).  
Unfortunately, despite the long existence of pharmacovigilance in Nigeria, NPC is yet to 
achieve the expected recommendation of 200 reports per million population target by WHO 
and this may be attributed to several factors such as declining health care standards, insufficient 
expertise in pharmacovigilance, increasing population burden, poor framework/infrastructure 
set-up, inadequate funding and resources dedicated towards pharmacovigilance, poor 
recognition of ADR, lack of focus and dedication towards pharmacovigilance by required 
parties/personnel, ADRs bulky/inefficient reporting process, and under-reporting from HCPs 
which contributes negatively to the feedback received by NPC (Olowofela, 2018). This is not 
only specific to Nigeria as other reviewed research on pharmacovigilance in other Africa 
countries shows pharmacovigilance activity is underappreciated due to similar issues especially 
insufficient expertise, lack of political goodwill, and poor funding contributes to the limitations. 
Unfortunately with the declining healthcare standards and increasing population burden over 
the years, only a notable drug-related event has been recorded as opposed to the burden of 
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ADRs that occur in the country, and this highlights the need to improve and be more focused 
towards pharmacovigilance in Nigeria healthcare system (Olowofela et al., 2016).  
2.4.2. Assessment and Reporting of ADRs in Hospital Settings 
ADR are frequent occurrence in hospital settings, and this can be attributed to several factors 
such as; complexity and severity of the disease, over-enthusiastic prescription, polypharmacy, 
drug interactions, and possible negligence. ADRs may be observed in about 10-20% of 
hospitalized patients, therefore hospital-based ADR monitoring and reporting programs can 
help identify and assess risk associated with drug usage. It is important to establish a systemic 
manner for assessing drug safety in hospital settings by having active surveillance, collection, 
and assessment of data regarding drug incidence, severity, and type of adverse events. 
Although accurate data are useful but measuring the incidence, nature, and severity of ADRs 
to a drug is not enough, it is also essential to assess patterns of ADRs against each other to 
identify their impact on patient lives (Gor and Desai, 2008).  
Due to the type of treatment offered in tertiary hospitals, most ADR evidence and cases arise 
from these settings because of the high risk associated with their treatments. A study conducted 
in USA by Agency for Healthcare Research and Quality (AHRQ) in 2011 established that 
causative relationship revealed that most frequent causes of an adverse event that occur during 
hospital stay were as a result of antibiotics, steroids, anticoagulants, and narcotics/opiates. It 
established that patients treated in tertiary hospitals have higher rates of adverse events as 
compared to patients treated in non-tertiary hospitals due to the type of therapy and drugs 
administered to them (Akhideno et al., 2019). Since diagnostic tests are often absent and re-
challenge is barely ethically justified, it is usually difficult to recognize if a clinical event is an 
ADR or it is due to the deterioration in the patient's primary condition. Hence, it is important 
to identify ADRs and demonstrate a causal relationship between the medicinal product and the 
untoward clinical event, although there are scales like the visual analogue scale that help 
physicians assess the severity of ADRs. Likewise, some vital factors can help to adequately 
recognize and assess causation. This includes; patients with certain health conditions like liver 
and renal dysfunction, Human Immunodeficiency Virus (HIV), patients in polypharmacy, and 
premature and aged patients (Doherty, 2009).  
According to a publication by Doherty (2009) on assessing probability of an ADR, the author 
established that ADR assessment was previously based on clinical judgment alone, but it is 
recognized that individual judgment may differ and that the semantics of the definitions are 
critical. This led to the development of several algorithms/decision aids to help improve the 
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scientific basis of causality assessment and reduce the disagreement between assessors. 
Algorithms were developed during the 70s and 80s, they provide standardized methods that 
help in recognizing ADR since they are structured system that is explicitly designed to facilitate 
ADR identification (Doherty, 2009). Their main advantage is associated with the feasibility of 
decentralizing causality assessment from medical diagnosis and extending it to different 
healthcare level i.e. pharmaceutical industry, academics, and health agencies.  It is important 
to consider the method of assessment used for assessment before validating an ADR report 
even though the quality of data and documentation influence the method reliability (Satyen, 
2013). 
Furthermore, the status of pharmacovigilance system in tertiary centres is unknown as regards 
it is effectiveness and functionality because the WHO indicators and related metrics for 
assessing these hospitals have just been newly published. In a study titled assessment of the 
state of pharmacovigilance in the south-south zone of Nigeria using WHO pharmacovigilance 
indicators by Opadeyi et., al (2018); the study was carried out in six tertiary institution hospitals 
in south-south Nigeria using a modified WHO data collection form to obtain the data. The data 
were analysed using both quantitative and qualitative methods based on WHO 
pharmacovigilance indicators. The authors established that one of the hospitals called UBTH 
performed better at the assessment as compared to other hospitals even though there was a 
general pharmacovigilance acceptance and structures were gradually put in place despite 
institutional challenges. Additionally, it was revealed that the processes and outcomes 
indicators were poor in all the facilities which was attributed to lack of awareness of measuring 
indices to monitor and evaluate pharmacovigilance, insufficient manpower, poor budgeting for 
pharmacovigilance, and poor record-keeping as regards routine data gathering and 
documentation of ADRs and other medicines-related events, (Opadeyi et al., 2018). 
The incidence of ADRs among hospitalized patients in the United Kingdom was stated around 
6.5% and admissions related to ADRs cost the national health scheme up to £466 million 
annually (Akhideno et al., 2019). Also, McKinsey & Co in 2012, established that 35 million 
preventable adverse drug events cost would be as high as the US $115 billion (Mckinsey, 
2012). Assessment and reporting systems of ADRs need to be robust and complete to be able 
to detect possible signals, new drug alerts, and improve the pharmacovigilance system. But the 
pharmacovigilance structure in most hospital settings is still in their infancy and the requisite 
culture to ensure effective operations is yet to be established. Therefore continuous ADR 
monitoring and causality assessment is essential in this settings as it can help to facilitate early 
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recognition of ADRs, reduce hospitalization stay and unnecessary burden associated with it, 
establish barriers to prevent ADRs recurrence and unexpected/serious drug effect, and in 
general improve the quality of patient treatment and their lives (Varallo et al., 2017). 
2.4.3. Completeness of Submitted ADRs Report  
In 1960s, WHO established a system to collect information about suspected ADR and this has 
been equally established in many countries by their respective pharmacovigilance centres. 
Unfortunately, despite the stated process, the incompleteness of submitted ADRs report to 
pharmacovigilance centres remains a global problem that hinders the effectiveness and 
complete evaluation of submitted ADRs report for drug causality.  
According to a publication on patterns of ADRs signals in NAFDAC pharmacovigilance 
activities by (Awodele et al., 2018), the study analysed a total of 935 reported ADRs for 6 
months and only 509 reports were complete and others have missing information such as the 
ADR start/stop date, suspected drug used, and other relevant requirement needed to validate 
the form. The outcome of the study was consistent with other published research on 
incompleteness of submitted ADRs reports to pharmacovigilance centres in countries like 
Saudi Arabia, Italy, and Mexico. The study suggested timely evaluation of received suspected 
reports for early detection of incomplete reports, and reporters should be reached and 
encouraged with incentives to facilitate sufficient and complete reports since NPC has no 
rejection policy for incomplete reports (Awodele et al., 2018).  
Completeness of spontaneous ADR reports submitted by general practitioners to a regional 
pharmacovigilance centre in Toulouse, France from 2010 to 2013 was analysed by Durrieu et 
al. (2016). The authors established that only 12.7% of the reports were classified as a well-
documented report using multivariate logistic regression to investigate potential factors 
associated with a well-documented report. While 68.5% were slightly documented and 18.8% 
were poorly documented (Durrieu et al., 2016).  Pharmacovigilance awareness for patients and 
training for HCPs should promote and emphasize the importance of completing an ADR reports 
forms regarding relevant data when reporting it, in order to optimize the evaluation of drug 
causality. 
2.5. Role of HCPs (HCPs) in Assessment and Reporting of ADRs 
The fundamental role of HCPs is to identify potential and actual medicinal products related 
issues, resolve them, and prevent reoccurrence. HCPs are encouraged to be actively involved 
in the monitoring, assessment, and reporting of ADRs to strengthen pharmacovigilance practice 
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and ADRs awareness, increase opportunities to review drug selection and incorporate sense of 
ownership. Since patients’ needs are changing, shifting from diagnosis and single acute 
problem treatment to long-term management of several interrelated chronic health conditions. 
HCPs need to adopt new parameters to proactively survey and monitor ADR continuously and 
integrates patient’s safety as core value and practice (Shewale et al., 2009). They are major 
stakeholders in achieving spontaneous ADRs reporting since they prescribe and follow up on 
treatment outcomes, thus they are best suited to detect ADRs based on the information gathered 
from their clinical observations and patients. HCPs have to ensure patients are aware of the risk 
of side effects and a suitable course of action in case they occur, but since reporting is based 
on voluntary participation, they are limited by under-reporting and a variance in quality of 
report received (Sriram et al., 2011).  
The involvement of tertiary hospitals is still quite slow in the implementation of most of the 
objectives stated in the pharmacovigilance policy, and there are fewer experts in the field which 
contribute significantly to the retarded growth of pharmacovigilance activity in the country. 
This is because the responsibility of reporting ADRs in these hospitals is majorly considered 
to be doctor's responsibilities since they are regularly reasoned to be the first among the list of 
ADRs primary reporters. Other HCPs such as pharmacists and nurses withdraw from this 
responsibility as they are less involved with patient management in tertiary hospitals, hence 
they feel less obligated to report ADRs. In contrast, nurses are more involved with patient 
management in primary health centres as well as pharmacists practicing in community 
pharmacies, they are in a privileged position to detect ADRs and even educate patients on the 
reporting process because of the direct contact they have with them. Considering the numbers 
and easy accessibility of primary health centres and community pharmacies in Nigeria, the 
influx of patients in these centres can significantly contribute towards better spontaneous ADRs 
reporting (Adisa and Omitogun, 2019). Furthermore, the role of pharmacists to become active 
stakeholders in the detection and reporting of ADRs has undergone profound changes over the 
last few years, especially in pharmacotherapy outcomes through the provision of 
comprehensive medication review services, and in encouraging direct patient reporting (Inácio 
et al., 2018). 
Error-free performance and great expectations are standard expected from HCPs, but the health 
system and personnel are not fail-proof, so errors are made with high human and economic 
costs. Lack of awareness, interest, time, aptitude, clinical acumen, confidence, and experience 
with assessment and reporting of ADRs has made lots of untoward adverse incidents pass 
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unnoticed, and this is a major deterrent that contributes to their slow/inactive involvement 
(Sriram et al., 2011).  
Additionally, the role of HCPs is important in correct drug usage, therefore their participation 
requires awareness and knowledge of pharmacological therapy, toxic profile of administered 
drugs, and drug product characteristics- such as warning, indications, and contraindications. 
This is critical to observe an ADR for proactive monitoring and reporting, and also a careful 
assessment of patient’s history and health condition can help prevent most ADRs associated 
with inappropriate prescription (Shewale et al., 2009). 
2.6. Reporting of ADRs by Patients  
For several years after the establishment of the ADR reporting system in the 1960s, only 
doctors could report ADRs. However, that changed over time has patients, pharmacists, and 
other HCPs are now allowed to report ADRs, even though some countries have still not 
accepted patient reporting in their national reporting programs (Aagaard et al., 2012). The 
history of patients reporting ADRs can be traced back to 1983 when it was first considered by 
a working party of the Committee on Safety of Medicines (CSM) after the withdrawal of 
benoxaprofen. In 2000, possible benefit is of patient reporting were summarised at the first 
international conference on consumer reports on medicines, which consists of the promotions 
of patients’ rights and equity, acknowledging that patients have unique experiences and 
perspectives, and their involvement would be beneficial to healthcare organizations.  ADRs 
could cause significant disability, morbidity, and mortality risk to patients’ lives therefore 
patients need to be encouraged and engaged actively in reporting ADRs, as monitoring and 
reporting of adverse drug reaction is vital to their safety.  The new pharmacovigilance 
legislation in the European Union introduced several changes which include the formal 
implementation of patient reporting, and this had led to the implementation of patient reporting 
systems in several countries (Inácio et al., 2018). Furthermore, it is widely known that 
underreporting of ADRs by HCPs is a substantial issue that needs to be addressed effectively, 
thus adding patients to the pool of potential reporters will help in earlier detection of significant 
ADRs, and boost spontaneous reporting (Avery et al., 2011). 
According to a research titled “evaluation of patient reporting of adverse reactions to the UK 
Yellow Card Scheme (YCS)” by (Avery et al., 2011), the study was carried out with submitted 
yellow card reports from patients (n=5180) and HCPs (n=20,949) from October 2005 to 
September 2007. The authors established that about one-third of their respondents expected 
feedback and motivations for reporting from the regulatory agency, while a few of them made 
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comments about HCP lack of awareness and dismissive attitude towards ADRs. A few of them 
stated that HCPs were unaware of patient reporting ADRs, discourage them from reporting, 
and refused to make a report on their behalf. Furthermore, the authors established that patients 
report described a more detailed reaction than that of HCPs, and it contained a higher median 
number of suspected ADRs per report, even though it was just 8.5% of the public population 
that were aware of the YCS. This report provided useful information on likely ADRs causality 
and impacts on patients’ lives, and also the outcome stated that the combined reports of patients 
and HCPs helped identified 47 new serious reactions that were not previously included in the 
Summaries of Product Characteristics (SMPC) (Avery et al., 2011). 
Another publication titled adverse drug reaction reporting in the UK; A retrospective 
observational comparison of yellow card reports submitted by HCPs and patients, the study 
analysed a total of 26, 129 yellow card reports from both HCPs (80.2%) and patients (19.8%) 
to compare patient characteristic and their report on suspected ADRs and suspected drugs with 
that of HCPs using the yellow card scheme. The authors established that the quality of reports 
of both HCP and patients were similar, and patients reported a higher proportion of suspected 
drugs and suspected ADRs than that of HCP -16.1% vs 9%, while HCPs mostly reported ADRs 
that are life-threatening (11.1 vs 6.2%), hospitalization (18.8% vs 12.9%) or caused death 
(2.6% vs 0.7%) than patients (McLernon et al., 2010). 
Unfortunately, just like HCPs, patients experience similar barriers such as insufficient 
awareness, uncertainty about responsibility for reporting, and lack of feedback for submitted 
reports. Providing continuous educational activities, dissemination of information in accessible 
language through HCPs or patients organization, and culture of simplicity and eliminating 
reporting barriers need to be aimed at and promoted by relevant authorities to actively integrate 
patient reporting (Inácio et al., 2018). A combination of both HCPs and patient reports can help 
generate more potential signals as compared to reports only from HCPs, and bridge the gap of 
underreporting on the part of HCPs. Patients are a major stakeholder in achieving spontaneous 
ADR reporting, and the true value of them reporting ADRs directly will remain unknown until 
more studies and evaluations are conducted. 
2.7. Perception of HCPs Towards Patients reporting ADR 
Healthcare professional’s perceptions towards patient reporting ADRs have not been 
extensively studied globally, only a few research has been conducted in countries such as 
Malaysia and UK, while other countries including Nigeria is yet to explore and evaluate the 
perceptions of it is HCPs towards direct patient reporting.  
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In a publication titled do health professionals have positive perception towards consumer 
reporting of ADR by Alshakka et al. (2013); The study was carried out using a cross-sectional 
mail survey to 104 participants which include 57 general practitioners and 47 community 
pharmacist in Penang island, Malaysia. The authors established that 88% of the participants 
agreed that patients reporting would contribute significantly to the existing pharmacovigilance 
program, and 97% also agreed that patients need more education regarding reporting of ADR. 
However, the authors stated that 68% of the participants were not aware that patients can report 
ADRs in Malaysia, while about 84% thought that patients cannot write a valid report as that of 
the HCPs (Alshakka et al., 2013). 
Another publication titled views of British community pharmacists on direct patient reporting 
of ADRs by krska (2013); the study was carried out using a questionnaire among 297 
community pharmacists in the UK. The author established that 85.2% of the respondent was 
aware of patient reporting, but only 57.9% had an accessible patient reporting form, while only 
18% displayed a promotional poster to facilitate patient reporting ADRs. The study also 
established that the majority of the respondent prefer the reporting process to be restricted only 
to HCPs. The respondents will rather do the reporting themselves than informing their patients 
about direct patient reporting because they feel patients need help to complete their medical 
history, and the yellow card form is too complicated for them to fill. Only 14% indicated they 
would create more awareness about patient reporting, and encourage their patient to report 
directly (Krska, 2013). 
Studies have shown that HCPs are pessimistic about the success of patient's direct reporting of 
ADRs. HCPs believe that patients do not have sufficient knowledge regarding their medicines 
and hazards, therefore they can’t produce quality information on ADRs nor generate a valid 
report. HCPs believe that ADR reporting is meant to be strictly restricted to them and patients 
are only meant to report ADRs through their healthcare providers. The above-mentioned views 
are still a barrier that needs to be extensively studied all over the world. 
2.8. Limitations of Assessment of ADR in Nigeria 
The main purpose of assessment and reporting is to enable rapid detection of potential signals 
related to drug use and identify rare and serious ADRs that may occur after drugs are marketed. 
However, there are well-known limitations such as variable quality of reported data, poor 
recognition of ADRs, underreporting, lack of information on drug exposure, and inability to 
use spontaneous ADR reporting to determine incidence or prevalence of ADRs since the 
characteristic of drug usage is unknown (Aagaard et al., 2012). Also, missing data and 
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incompleteness of submitted reports to pharmacovigilance centres is a significant limitation, 
especially in developing countries like Nigeria.   
In developing countries like Nigeria, there is minimal information on the in-hospital incidence 
of ADRs, and the culprit medications, this is because the assessment and reporting medium in 
Nigeria is inadequately efficient and somehow being underutilized by Nigerians including the 
HCPs and healthcare providers. HCPs sometimes do not report ADRs because they find it 
challenging to establish with certainty the potential causal relationship between a drug and an 
adverse reaction (causality assessment). However, according to a vital principle of 
pharmacovigilance, it is important to report even suspicion to generate an alarm in the interest 
of protecting public health (Palleria et al., 2013). Additionally, this information is useful for 
health management, planning, budgeting, formulation of policy, and for the development of 
treatment protocol required to ensure appropriate and optimal patient care (Akhideno et al., 
2019). 
 The aim of institutionalizing pharmacovigilance in Nigeria healthcare facilities both at state 
and federal level is still the main objective that is yet to be achieved, there is need for more 
capacity building to viable train HCPs on assessing suspected ADRs. Also, there is need to 
categorize and assess the ADRs related to herbal medicines which are broadly used by the 
Nigerian population. Furthermore, lack of active patient involvement in the reporting system 
contributes to the underreporting as patients are major stakeholders in achieving spontaneous 
ADRs reporting which is a global phenomenon and the cornerstone of pharmacovigilance 
activity, therefore their impact needs to be evaluated and strengthened  (Adisa and Omitogun, 
2019).  
2.9. Conclusion 
Following a comprehensive review of published articles and papers, it is obvious that ADR 
reporting and assessment culture are not well established as depicted by the huge gap between 
encountered ADR and it is reporting trend among HCPs. Although HCPs have a positive 
attitude towards assessing and reporting ADR, however, they have poor knowledge and 
practice towards it, hence ADR workshops and training should be conducted worldwide to 
provide guidance and update their knowledge, while good pharmacovigilance practice should 
be developed according to international standards. Pharmacovigilance systems are essentials 
and their knowledge could be further improved, therefore increased institutionalization of 
pharmacovigilance and improvement in medical record documentation should be incorporated 
into pharmacovigilance activities in tertiary hospitals. Furthermore, patients should be 
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educated and engaged as regard reporting of ADRs, as this will help achieve a better 
spontaneous report, generate possible signals, and reduce ADRs that could have otherwise been 
prevented.   
Since ADRs are unavoidable risks associated with medicinal products, it is essential to develop 
an effective process for it is assessment, monitoring, and reporting process to invariably 
contribute to the overall pharmacovigilance structure in place in Nigeria and other parts of the 
world.   
2.10. CONCEPTUAL FRAMEWORK 
     










CHAPTER 3: RESEARCH METHODOLOGY 
3.1. Overview 
This dissertation was modelled on a mixed-method research methodology which includes 
qualitative and quantitative methods, it was based on the use of deductive survey questions. 
The researcher chose mixed-method to overcome the constraints of a mono-method by using 
the qualitative data to complement her quantitative data. The study was exclusively conducted 







1. Methodology Quantitative Qualitative 
2. Philosophy Positivism Interpretivism 
3. Selection Criteria Medical doctors, Nurses, 
Pharmacist, and Patients in 
tertiary hospitals 
Medical doctors, Nurses, and 
Pharmacists in tertiary hospitals. 
4. Data Collection 
Source 
Highly structured questionnaire Semi-structured phone interviews 
5. Structure 5 sections which consist of 21 
questions 
10 questions which lasted for 30 
minutes on average. 
6. Sampling 
Technique 
Random sampling  Purposive/Snowballing sampling 
7. Sampling Frame 450 participants targeted; 405 
response was successfully 
obtained 
6 highly experienced HCPs 
 Table 2: Overview of research design and primary data collection created by the author 
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3.2. Research Study Setting and Population 
Lagos is the largest populated state in Nigeria and in sub-Saharan Africa state in the south-
western geopolitical zone of Nigeria, it has a current population of over 14 million people in it 
is cities and urban areas. The state has five administrative divisions which are further divided 
into 37 local government areas (Population Stat, 2020a).  
Based on Healthcare Facilities Monitoring and Accreditation Agency (HEFAMMA) statistics, 
Lagos state consists of 26 registered general hospitals, 256 public health centres, and 2,886 
specialists/private hospitals. It has one of the most efficient healthcare systems in the country 
based on the high numbers of primary, secondary, and tertiary centres present in the state. This 
study was focused on all categories of tertiary hospitals in Lagos state because these hospitals 
have the widest access to all cadres of HCPs and patients which helped the researcher to get 
diverse data on spontaneous ADRs assessment and reporting.  
3.3. Research Approach  
As shown in the table above, the researcher used a mixed-method approach to gather her 
primary data, which includes; quantitative approach using a questionnaire to collect relevant 
data from a reasonable number of HCPs and patients, and a qualitative approach using phone 
interview to explore information from a selected number of highly experienced HCPs to 
support her findings.   
The quantitative approach was aimed at obtaining insight from the practice of HCPs towards 
direct patient reporting, and ADRs assessment and reporting process. And to also obtain 
applicable information from patients as regards their knowledge and awareness on ADRs 
reporting. This was facilitated through the use of an electronic survey that generated rich 
descriptive data from the participants while eliminating any risk of bias, influence, and 
maintain minimal interactions with them.  On the other hand, the qualitative approach was 
aimed to draw out insights and explore in-depth information from the practice of selected HCPs 
on their perception towards direct patient reporting, and the assessment and reporting of ADRs 
in Nigeria tertiary hospitals. This was facilitated through a semi-structured phone interview 
which led to the generation of in-depth explanatory data. The combination of these two 
approaches enabled the researcher to gather a wealth of data that was used for quantifiable 
measures for statistical analysis. 
The questions were drafted in a way that has a feel of the human element to understand the 
perceptions of HCPs towards direct patient reporting ADRs and establish awareness about the 
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existing assessment and reporting process in tertiary hospitals. Also, the researcher ensures her 
questions were addressing the most important issues in her research study, which enabled her 
to propose feasible recommendations and improvements that will invariably contribute to the 
overall pharmacovigilance structure in place in tertiary hospitals which can be sustainable over 
a long period. 
A deductive approach was used rather than an inductive approach because the concepts of this 
study were operationalized in a way that enables facts to be measured quantitatively while 
ensuring clarity of definition. This approach enabled the cause-effect link between findings, 
and the researcher was independent of what was being observed (Saunders et al., 2009). It also 
helped ensure reliability and validity of data, and envisage the certainty of this study through 
the application of controls. After the analysis of the data collected from respondents, the 
findings were compared to other applicable literature in the field and public views to check that 
they are in-line and in agreement with the already established norms and to clearly express the 
researchers concluding view on the research being conducted. 
3.4. Research Philosophy 
The fundamental philosophy of this research is a Positivism and Interpretivism, it was 
implemented for this study to obtain quantifiable observation which was useful for statistical 
analysis of information gathered from participants, and to derive an appropriate conclusion. 
The positivism philosophy helped facilitate replication of response from respondent through 
the use of a highly structured questionnaire which was distributed electronically to the group 
of participants. The researcher was independent of what was been observed and only 
concentrated on the fact available without any human interference or bias within the study. The 
research progress through hypothesis that required the use of large randomly selected samples 
of HCPs and patients which were easily measurable.  
The usage of Interpretivism philosophy for the qualitative approach was due to the subjectivity 
involved since all participants selected for the interview process had different perspectives 
about ADRs assessment and reporting practice. Also, several factors such as their services, 
process, patients size, and policy on pharmacovigilance had an impact on their reporting 
system, and this helped to frame the information obtained via phone interview which resulted 
in data that was shaped by their individual interpretation, values, and perspective of reality 
based on their experience and belief.  
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A combination of descriptive and explanatory research was adopted for this research to gather 
information from 411 respondents via online survey and telephone interview. For the 
descriptive research, the researcher identified and described the variability in different 
phenomenon without any form of bias or interference with the data gathered through analysing 
the perception of HCPs towards direct patient reporting of ADRs, and towards the assessment 
and reporting process in their hospitals. Also, it analysed patient knowledge and awareness as 
regards the ADR reporting. For the explanatory research, the researcher examined and 
explained the relationship between the variables such as opinion, behaviour, and attribute 
variables of the respondents. 
3.5.  Research Strategy 
To fulfil the research objective, a mixed-method approach was used. The strategy of this 
research was to analyse the perception of HCPs towards direct patients reporting ADRs and 
the assessment and reporting process of ADRs in Lagos state tertiary hospitals. It was aimed 
to evaluate the awareness and knowledge of ADR reporting among patients to determine the 
challenges they face while reporting. Therefore, the researcher used deductive survey questions 
to gain a better understanding of the issue and context involved in the study.  
Two different questionnaires were administered to the groups to obtain applicable information 
from them. For HCPs, a goggle form which consisted of 21 questions was used for the 
questionnaire. While for the patients, a google form that consisted of 19 questions was used for 
the questionnaire. The questions were structured under 5 sections which facilitated the 
collection of the demographic data and opinions of the respondents respectively to fulfil the 
goal of the study. The categorical data method was used for the questions to ease subsequent 
data analysis upon the collection of information from the respondent. To strengthen the 
philosophy of the positivism approach, the survey was completed in the absence of the author, 
and all response gotten was a free expression of opinions without any risk of bias, influence, 
and interactions with the respondent. 
The first part of the survey was a plain language statement that was designed to explain the aim 
of the study to the participants and gain their consent to use their answers exclusively for the 
research purpose only. Participants were assured that their participation was completely 
voluntary, and the privacy of every participant is highly assured as all responses will be fully 
anonymous and strictly confidential. They were also informed that all generated data will be 
stored in line with the General Data Protection Regulation (GDPR). 
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3.6. Data Collection 
As detailed in the research strategy, the researcher collected her primary data through the use 
of a highly structured questionnaire which was designed for both patients and HCPs of Lagos 
state tertiary hospitals considered for the study.  All questions were designed to tackle the 
relevant information needed to successfully ascertain the opinions of the HCPs and patients in 
the aforementioned study site to achieve the research aims and objectives.  
According to Saunders et.al 2009, the best approach to achieve a great outcome of an 
exploratory study is to use a semi-structured or unstructured interview. Therefore, to support 
my quantitative findings, a semi-structured interview was used to help achieve exploration 
studies, the researcher used this method to facilitate further inquiry from the participants about 
their answer to get a better understanding of their answers and the impact/influence behind the 
answers given by asking them to further explain their answers. The respondents were asked a 
list of questions that slightly varied from interview to interview. The interview approach helped 
the researcher disclose areas previously not considered which helped contribute significantly 
to fulfilling her research objectives, achieve robust and very detailed data, and/or restructuring 
her approach or questions. 
3.7. Sources of Data 
 
                                                     Figure 7: Sources of data, created by the author 
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To fulfil research aims and objectives, the researcher used both primary and secondary data to 
gather information. The primary data was the main source of information and it consisted of 
21 questions for HCPs and 19 questions for patients which were used to gather relevant data 
for her research. The researcher gathered information from 405 participants which included 
135 HCPs and 270 patients. 
The source of the research primary data included; contacts derived through professional alumni 
forum of teaching hospitals in Lagos, networking and LinkedIn contacts, referral from relatives 
that are healthcare professionals, referral from her family doctor, referrals from friends that are 
health professionals, and ex-colleagues and their referrals. Furthermore, sources of the 
secondary data includes- peer-reviewed journals and articles, accredited websites, databases, 
and academic write-ups. 
3.8. Sampling Plan 
This study sampling frame for the quantitative methodology consists of 405 participants which 
include 135 HCPs, and 270 patients from different tertiary hospitals in Lagos state Nigeria. A 
random sampling technique was employed to choose the participants to ascertain fair 
participation in the survey.  While for the qualitative methodology, purposive and snowballing 
sampling techniques were deemed appropriated to select 6 highly experienced HCPs which 
include 2 doctors, 2 pharmacists, and 2 nurses in different tertiary hospitals in Lagos State. 
This sampling plan was chosen because it requires using a group of people who 
shows/experience a similar phenomenon of interest which in turn helps the researcher to get 
vital and reliable information needed to fulfil research purpose. 
3.9. Access and Ethical 
Accessibility of data is very crucial for the completion of a research and it is important for 
researchers to consider the extent and nature of access required to meet set objectives, and to 
also consider how they will gain sufficient access required to meet their objectives and 
complete their research. The researcher used her familiarity and understanding of the tertiary 
hospitals to gain access to her research data source, she used her existing contact of HCPs to 
get referrals to develop new contacts that helped contribute to her data source (Saunders et al., 
2009). 
Before commencement of the interview, an audio-based briefing was given to each respondent 
to explain the purpose of the research and why she’s researching that it is part of her academic 
requirement to fulfil her master’s program, and highlight the possible benefit is of the research 
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to the hospital to ensure she gains sufficient access required to fulfil her research objective and 
completion. Furthermore, she clearly defines the type of access required and provided a brief 
introductory explanation of the research to the participants to enable them to have a clear 
insight of the study and to ensure their reply corresponds with the research objectives. 
Concerning the ethics, the researcher ensures that all questions asked in the questionnaire and 
during the interview requested no personal information of the participants, and they were 
strictly related to the study and it is objective. It was clearly stated that the study was voluntary, 
and they can opt to withdraw or stop at any point they wish to. Furthermore, in compliance 
with Griffith College Dublin regulations and guidelines, the respondents informed consent was 
obtained before conducting the interview stating that their identity would be completely 
anonymous and a consensus was asked before audiotaping the interview. She ensured the 
interview was conducted professionally and ethically which did not subject her study group to 
any form of harm or embarrassment.  After a complete agreement and understating of all the 
stated criteria and conditions, the interview was conducted and recorded simultaneously. The 
researcher treated all data obtained with optimum confidentiality and anonymity, and ensure 
they are not misinterpreted while transcribing it.  
3.10. Techniques for Data Analysis 
The quantitative data collected from the respondents were analysed using statistical methods 
because the data was quantifiable. Statistical Package for Social Sciences (SPSS) tool was used 
to analyse the results, and chi-square test was used as an appropriate descriptive statistic of 
frequencies and percentages to test relationships between categorical variables, assess the 
uniformity of data collected from the respondents, and to display the distribution of responses. 
The test was used to determine if there is a statistically significant difference between the 
expected and observed frequencies to test that the variables are independent in one or more 
categories.   
For the qualitative data, the data obtained from the respondents were analysed through 
Deductive Thematic Analysis approach as the analysis technique to capture a rich and more in-
depth data and provide a description and understanding of the answers obtained from 
respondents. Thematic analysis can be described as a method in which patterns and topics are 
defined, analysed, and interpreted. This method of data analysis proceeds through six models 
which include (I) Familiarization- transcribing the audio and reading through the transcribed 
text; (II) “Coding” of texts to highlight similar response pattern and important points from 
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respondents; (III) Generating themes through coded text; (IV) Reviewing of themes; (V) 
Defining and renaming of the themes; and (VI) Producing the report by writing up a theme to 
appropriately capture research observation and conclusions (Nowell et al., 2017).  
3.11. Conclusions 
A research methodology is an integral part of research investigations, it highlighted specific 
tools and methodology employed by the researcher. For this research, a mixed-method 
approach that was underlined by a positivist philosophy was adopted. This approach led to 
quantitative and qualitative approached for data collection; an online survey, semi-structured 
phone interview, and the techniques used to analyse the data obtained were explained alongside 
how ethical concerns and their implications were handled. This ensured a better insight and 
perspective on the research study as well as obtaining measurable facts required for the 
analysis. 
The data obtained were compared to the findings gathered during the literature review which 
was discussed in the previous chapter. The findings and analysis of data obtained from 













CHAPTER 4: RESEARCH FINDINGS AND ANALYSIS 
4.1. OVERVIEW 
This chapter presents the analysed results of answers generated from the survey questionnaire, 
a total of 405 responses were obtained and qualified for data analysis. The data generated 
assisted the author to determine the awareness, knowledge, and hindrances encountered by both 
HCPs and patients, as well as the opinions of HCPs towards direct patients reporting of ADRs. 
Descriptive statistics and percentages were used to present the data, and the data were analysed 
using google forms, SPSS, and chi-square tests.  
 
4.2. ANALYSIS OF HCPs RESPONSES 
Response Rate: The survey was administered to a total of 150 HCPs for 18 days 
(23rd July – 9th August). It consisted of 50 doctors, 50 pharmacists and 50 nurses, 
135 accepted responses were received resulting in a response rate of 90%.  
4.2.1. HCPs Demographics (Question 1 – 3) 
 
Table 3: HCPs Demographics 
 n % 
1. Which healthcare 
professional is completing 
this survey? 
Doctor 38 28.1 
Nurse 29 21.5 
Pharmacist 54 40.0 
Pharmacologist 5 3.7 
Others 9 6.7 
2. How long have you been 
practicing in this field? 
Less than 1 year 15 11.1 
1 - 5 years 66 48.9 
6 - 10 years 31 23.0 
More than 10 years 23 17.0 
Table 3 presents demographics of HCPs that responded to the study. It could be seen from the 
result that 28.1% of the respondents were doctors, 21.5% were nurses, 40.0% were pharmacists, 
3.7% were Pharmacologists and 6.7% were in other specialist professional categories. The 
distribution of respondents based on their length of practice showed that 11.1% had practiced 
for less than a year, 48.9% had practiced for 1 – 5 years, 23.0% had practiced 6 – 10 years and 
17.0% had practiced more than 10 years. 
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4.2.2. Level of Awareness/Knowledge about ADR 
• Question 3-5:  
Of all the respondents, 77.8% of the respondents are aware of ADR definition by considering 
it to be unexpected/serious reaction after taking a drug, while 14.8% considered it to be any 
reaction from drug therapy, 7.4% considered it to be expected and predicted reaction, 
establishing that have no basic knowledge of ADR definition.  
On knowledge of organizations responsible for handling ADRs reports and pharmacovigilance 
in Nigeria, the distribution showed that 13.3% considered it to be the Federal Ministry of 
Health, 71.9% considered it to be NAFDAC, 8.9% considered it to be NCDC while 5.9% stated 
that they do not know. 
The distribution of respondents’ knowledge about whether the assessment and reporting of 
ADRs were incorporated into the orientation program curriculum of newly employed HCPs in 
their hospital showed that 48.9% considered that it was so, 34.8% considered that it was not so 
and 16.3% stated that they do not know. 
  
Table 4: Knowledge about ADR 
 N % 
3. What is your understanding of ADR 
(ADRs)? 
Unexpected/Serious reaction 
after taking a drug 
105 77.8 
Any reaction from a drug 
therapy 
20 14.8 
Expected and predicted 
reaction 
10 7.4 
Total 135 100.0 
4. Which of the following organization is 
responsible for handling ADRs reports and 
Pharmacovigilance in Nigeria? 
Federal Ministry of Health 18 13.3 
Nigerian Agency for Food 
and Drug Administration and 
Control (NAFDAC) 
97 71.9 
Nigeria Centre for Disease 
Control (NCDC) 
12 8.9 
I do not know 8 5.9 
Total 135 100.0 
5. Is assessment and reporting of ADRs 
incorporated into the orientation program 
curriculum of newly employed HCPs in your 
hospital? 
Yes 66 48.9 
No 47 34.8 
I do not know 22 16.3 




It is an interesting fact that a good number of the HCPs are aware of ADR basic knowledge 
and correctly stated NAFDAC as the organization responsible for handling submitted ADR 
reports in Nigeria. However, only 48.9% stated that it is incorporated into their orientation 
curriculum at their hospital. This implies that although a significant number of the respondents 
are aware of ADR definition but they do not have it in their hospital program, therefore their 
level of knowledge is purely theoretical and personal. 
• Question 6-9: 
Table 5 shows distribution of awareness about ADR assessment among the respondents. It 
could be seen from the result that majority of HCPs (n = Yes) agreed that they are not aware 
of how causality of ADRs is performed in Nigeria (60.0%). Among those who expressed 
knowledge, 18.0% considered it to be a traditional routine in their hospital while 82.0% did not 
consider it to be so. 
Also majority of HCPs were aware of the standard procedure for ADR assessment and 
reporting in their hospital (52.6%). However, there was an equivocal opinion on whether there 
was an adverse event and therapeutic committee in their hospital as 50.4% agreed that there 
was and 49.6% disagreed. 
 
Table 5: Awareness about ADR Assessment 
 
No Yes Total 
n % n % n % 
6. Are you aware of how causality assessment of ADRs is 
performed in Nigeria? 
81 60.0 54 40.0 135 100.0 
7. If yes, Is it a traditional routine in your hospital? 111 82.0 24 18.0 135 100.0 
8. Are you aware of any standard procedure for ADR 
assessment and reporting in your hospital? 
64 47.4 71 52.6 135 100.0 
9. Is there adverse drug events & therapeutic committee in 
your hospital? 
68 50.4 67 49.6 135 100.0 
This shows that majority of HCPs have no prior knowledge about causality assessment of ADR 
even though there is a standard procedure for it in their hospital. This can be attributed to the 
fact that it is not a traditional routine in most of the tertiary hospitals as stated by the 
respondents, and there is no adverse drug events & therapeutic committee in the hospital to 
help evaluates clinical use of drugs and develop applicable policies for managing drug 





• Question 10-13: 
Table 6 examines HCPs opinions on ADR reporting and their frequency on reporting it. The 
results showed that most of the respondents considered that ADR assessment and reporting 
should be mandatory (87.4%) while 12.8% opined that it should be voluntary. Majority of them 
have observed ADR cases in their practice (82.2%) and in response to how often they reported 
ADR cases, 37.8% stated that they always reported it, 14.4% often reported it, 20.7% 
sometimes report it, 23.4% rarely report it while 3.6% never report. Finally, in response to the 
basic principles of reporting ADR, the most identified principle was completeness of report 
(77.0%) followed by timeline of reporting ADRs (68.1%) and reliability of patient judgment 
(60.7%). 
 
Table 6: Knowledge about ADR 
 n % 
10. In your opinion, do you think ADR 
assessment and reporting should be 
either? 
Mandatory 118 87.4 
Voluntary 17 12.6 
Total 135 100.0 
11. Have you observed any ADR 
cases in your practice? 
Yes 111 82.2 
No 24 17.8 
Total 135 100.0 
12. If yes, how often do you report it? Always 42 37.8 
Often 16 14.4 
Sometimes 23 20.7 
Rarely 26 23.4 
Never 4 3.6 
Total 111 100.0 
13. basic principles of reporting ADR Completeness of report 104 77.0 
Timeline of reporting ADRs 92 68.1 
Reliability of patient judgment 82 60.7 
I do not know 9 6.7 
Total 135 100.0 
As established from the table, majority of HCPs opted that ADR assessment and reporting 
should be a mandatory obligation in Nigeria and they correctly identified most of the basic 
criteria for reporting ADR, which indicates that they are aware of the importance of reporting 
ADR. However, they stated they have observed ADR cases in their practice within the past 12 




• Question 14-15: 
As depicted from the answers on table 7, it could be seen that most of them stated that they 
were not aware of the SMS short-code for reporting ADR in Nigeria (85.9%); and they do not 
think they were sufficiently trained and knowledgeable about how to assess and report ADRs 
(62.2%). 
 
Table 7: Knowledge about ADR reporting 
 
Yes No Total 
n % n % n % 
14. Are you aware of the SMS short-code for reporting ADR in Nigeria? 19 14.1 116 85.9 135 100.0 
15. Do you think you are sufficiently trained and knowledgeable about how to 
assess and report ADRs? 
51 37.8 84 62.2 135 100.0 
In all the respondents, majority of them established that they have not heard of the SMS short 
code, and they stated that they have no sufficient knowledge about how to assess and report 
ADRs because they are not viable trained on it.  
 
4.2.3. HCPs Perceptions Towards Direct Patient Reporting of ADRs 
• Question 16-19: 
Table 8 presents HCPs opinions about patients reporting ADRs. The result showed that most 
of them were not aware that NPC in Nigeria allows patients to report ADRs directly (59.3%), 
most thought reports given by patients can be a good source of ADRs information (77.8%), 
most do not think that patients can write valid and quality ADR reports compared to HCPs 
(85.9%) and they do not encourage direct patient reporting of ADRs rather than through their 
HCPs (67.4%). 
 
Table 8: HCPs Perception towards patient reporting ADRs 
 
Yes No Total 
n % n % n % 
16. Are you aware that the National Pharmacovigilance Centre (NPC) in 
Nigeria allows patients to report ADRs directly? 
55 40.7 80 59.3 135 100.0 
17. In your opinion, do you think the reports given by patients can be a 
good source of ADR information? 
105 77.8 30 22.2 135 100.0 
18. Do you think patients can write valid and quality ADR reports 
compared to HCPs? 
19 14.1 116 85.9 135 100.0 
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19. Do you encourage direct patient reporting of ADRs rather than 
through their HCPs? 
44 32.6 91 67.4 135 100.0 
As established from the result, HCPs are not aware that patients can report directly to NPC, 
however the respondents seem to think their report can be a good source of ADR information 
if they make a report. Sadly, they have an opposing opinion that patients can’t generate a valid 
and quality report like HCPs, and there was a broad agreement that they should not be allowed 
to report directly to NPC rather the report should go through their physicians to ascertain the 
quality before submitting to NPC. 
 
4.2.4. Challenges of Reporting ADRs in Lagos State Tertiary Hospitals 
This section presents the challenges encountered by HCPs during their ADR practice in Lagos 
state tertiary hospitals. The researcher presented the participants several options to help 
ascertain their opinions on possible hindrances they are facing. 
• Question 20: 
Table 9: Hindrances to ADR Reporting 
 n % 
Insufficient information provided by the patient 103 76.3 
Lack of knowledge on ADRs reporting 87 64.4 
Too busy and not enough time to prepare and send an ADR report 67 49.6 
Rigorous or complex reporting process 60 44.4 
Inaccessibility of ADR report form 57 42.2 
The urge not to report an already established ADR 52 38.5 
Fear of facing legal penalty 49 36.3 
Level of clinical knowledge makes it difficult to diagnose an ADR 43 31.9 
Others 2 1.5 
Table 9 revealed the hindrances of ADR reporting encountered by HCPs in tertiary hospitals. 
Based on the responses, majority agreed that most common hindrances to ADR reporting are 
insufficient information provided by the patient (76.3%), and lack of knowledge on ADRs 
reporting (64.4%), while others included, too busy and not enough time to prepare and send an 
ADR report (49.6%), rigorous or complex reporting process (44.4%), inaccessibility of ADR 
report form (42.2%), the urge not to report an already established ADR (38.5%), fear of facing 
legal penalty (36.3%), level of clinical knowledge makes it difficult to diagnose an ADR 
(31.9%) and others which include insufficient staffs and too much workload (1.5%). 




4.2.5. Recommendations for Improvement 
This section presents the proposed recommendation for the respondents to choose from by 
agreeing or disagreeing to the provided options. 
• Question 21: 
Table 10: Recommendations towards ADR reporting 
 
Strongly 
Disagree Disagree Neutral Agree 
Strongly 
Agree 
n % n % n % n % n % 
Increase awareness about pharmacovigilance by 
conducting conference and continuous education 
programs 
0 .0 1 .7 6 4.4 29 21.5 99 73.3 
Current regulations should be reviewed to make ADRs 
reporting a professional obligation 
0 .0 1 .7 12 8.9 36 26.7 86 63.7 
NPC should provide feedback for every reported 
ADRs 
0 .0 0 .0 7 5.2 42 31.1 86 63.7 
Pharmacovigilance and ADRs module should be 
incorporated into medical/nursing school curriculum 
1 .7 0 .0 12 8.9 36 26.7 86 63.7 
Patients need more education and awareness on ADR 
reporting 
0 .0 2 1.5 15 11.1 41 30.4 77 57.0 
Initiatives to encourage more direct patient reporting 2 1.5 6 4.4 38 28.1 46 34.1 43 31.9 
Introduction of technological solutions to assist HCPs 
to collate past medical history towards ADRs 
assessment 
0 .0 0 .0 16 11.9 46 34.1 73 54.1 
Table 10 presents the distribution of responses on recommendation towards ADR reporting 
among the respondents. Interestingly, an overwhelming majority of respondents agreed 
(strongly agree + agree) to most of the proposed recommendations, however giving initiatives 
to encourage direct patients reporting which stated 66.0% seems to be the lowest agreed 
recommendation. 
 94.8% respondents agreed to increase awareness about pharmacovigilance by conducting 
conference and continuous education programs. 90.4% respondents agreed that current 
regulations should be reviewed to make ADRs reporting a professional obligation. 
NPC should provide feedback for every reported ADRs (94.8%), pharmacovigilance and ADRs 
module should be incorporated into medical/nursing school curriculum (90.4%), patients need 
more education and awareness on ADR reporting (87.4%), initiatives to encourage more direct 
patient reporting (66%), and that introduction of technological solutions to assist HCPs to 
collate past medical history towards ADRs assessment (88.2%). 
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This established that the proposed recommendation can help achieve a viable and sustainable 
pharmacovigilance practice when adequately put in place. 
 
 
4.3. ANALYSIS OF PATIENTS’ RESPONSES 
Response Rate: The survey was administered to a total of 300 patients for 18 days 
(23rd July – 9th August). 270 accepted responses were received resulting in a 
response rate of 90%.  
 
4.3.1. Patients Demographics (Question 1-4) 
Table 11 presents patients’ demographics who responded to the study. The result from the table 
showed that 47.8% of the patients were female and 52.2% were male. The age distribution of 
patients showed that 60.4% were predominantly young adults aged between 18 – 30 years, 
25.6% were 31 – 40 years, 10.0% were 41 – 50 years, 3.3% were 51 – 60 years while 0.7% 
were 61 years and above. The distribution of respondents’ highest level of education showed 
that 64.1% had postgraduate education, 29.6% had undergraduate education, and 6.3% had 
secondary education. Finally, the distribution of patients’ occupation showed that 7.8% were 
academic professionals, 35.6% were corporate/office workers, 28.9% were self-employed, 
22.2% were students and 5.6% were unemployed. 
 
Table 11: Patients Demographics 
 N % 
Gender Female 129 47.8 
Male 141 52.2 
Total 270 100.0 
Age 18 - 30 years 163 60.4 
31 - 40 years 69 25.6 
41 - 50 years 27 10.0 
51 - 60 years 9 3.3 
61 and above 2 .7 
Total 270 100.0 
What is your highest level of 
education? 
Postgraduate 173 64.1 
Undergraduate 80 29.6 
Secondary education 17 6.3 
Total 270 100.0 
Academic Professionals 21 7.8 
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Which of these categories do 
you belong to? 
Corporate/Office Worker 96 35.6 
Self Employed 78 28.9 
Students 60 22.2 
Unemployed 15 5.6 
Total 270 100.0 
 
4.3.2. Patients Level of Awareness/Knowledge 
• Question 5-9: 
This section presents the opinions and distribution of patients’ response on reporting of ADRs. 
Of all the respondents, 63.3% have experienced ADR, 29.3% have not experienced it while 
7.4% do not know. Among the respondents who have experienced an ADR, most action that 
patients had taken in response to the experienced ADR is stopped using the drugs (43.3%), 
while others include, informed a healthcare professional (36.3%), did nothing because the 
reaction was tolerable/stopped on it is own (17.0%), treated ADR with another drug (2.3%) or 
changed to a different drug type to continue original therapy (1.2%). 
Majority of the patients stated that they knew how to report an adverse drug reaction when they 
notice one (73.3%). The people to whom they would report to included doctor/nurse (74.7%), 
pharmacist (15.2%), NPC (8.1%) or a relative (0.5%).  
As for how they became aware of ADR, the distribution shows that their common sources of 
information are patient information leaflet from the drug (28.9%), followed closely by the 
internet (26.7%), and HCPs (26.3%). While 9.6% stated that they knew about ADR through 
relative/friend and television/radio (2.2%), whereas 6.3% stated that they do not know what 
adverse drug reaction was. 
Table 12: Experience with ADR 
 N % 
Have you ever experienced 
an adverse drug reaction? 
Yes 171 63.3 
No 79 29.3 
I do not know 20 7.4 
Total 270 100.0 
If yes, what action did you 
take when you experienced 
it? 
Stopped using the drug(s) 74 43.3 
Informed a healthcare professional (doctors, nurses, 
pharmacists) 
62 36.3 
Did nothing because the reaction was 




Treated ADR with another drug 4 2.3 
Changed to a different drug type to continue original 
therapy 
2 1.2 
Total 171 100.0 
Do you know how to report 
an adverse drug reaction 
when you notice one? 
Yes 198 73.3 
No 72 26.7 
Total 270 100.0 
If yes, to whom do you report 
the adverse drug reaction? 
Doctor/Nurse 148 74.7 
Pharmacist 30 15.2 
National pharmacovigilance centre (NPC) 16 8.1 
Relative 1 .5 
Declined to indicate 3 1.5 
Total 198 100.0 
Which of the following 
sources did you obtain 
information about ADR? 
HCPs (doctors, nurses, pharmacist) 71 26.3 
Patient information leaflet from the drug 78 28.9 
Internet 72 26.7 
Relative/Friend 26 9.6 
Television/Radio 6 2.2 
I do not know what adverse drug reaction is 17 6.3 
Total 270 100.0 
This established that majority of patients have a basic understanding of what ADR is, but they 
are not aware of reporting directly to NPC rather will report to their HCPs or stopped using the 
drug. This depicts lack of awareness on basic reporting methods available to patients within 
their reach.  
• Question 10-15: 
As a follow up question to question 10-15, this section is to ascertain patients experience in 
reporting ADRs. Table 13 shows the distribution of patients’ opinions on the reporting of ADR. 
The majority of the patients (64.4%) stated that they had never reported an ADR while 35.6% 
stated that they had. Among those who had ever reported an ADR, when asked how easy was 
the reporting process ranging from 1 which represented very difficult to 5 which represented 
very easy, 5.0% stated that the process was 1, 16.0% considered that the process was 2, 32.0% 
indicated that it was 3, 21.8% stated that it was 4 and 25.2% stated that it was 5.  
Most of the patients stated that they were not discouraged from making a report (75.0%) 
compared to 25.0% who stated they were discouraged. (43.9%) of the respondents got feedback 
concerning their report, 32.3% did not get feedback and 23.8% were not sure. Most of the 
patients never reported an adverse drug reaction (58.0%), while 25.7% had reported once, and 
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16.3% had twice or more. The majority of the patients established that they never reported 
ADR when they notice it (45.4), while 21.5% report immediately after noticing it, 18.0% 
reported within a week, 8.3% within the month, and 6.8% more than a month later. 
 
Table 13: Patient Reporting ADR 
 n % 
Have you ever reported an adverse 
drug reaction? 
Yes 96 35.6 
No 174 64.4 
Total 270 100.0 
If yes, how easy was the reporting 
process? 
1 6 5.0 
2 19 16.0 
3 38 32.0 
4 26 21.8 
5 30 25.2 
Total 119 100.0 
Were you at any point discouraged from 
making a report? 
Yes 67 25.0 
No 203 75.0 
Total 270 100.0 
Did you get feedback concerning your 
report? 
Yes 72 43.9 
No 53 32.3 
Not Sure 39 23.8 
Total 164 100.0 
How many times have you reported 
ADR? 
Never 157 58.0 
Once 69 25.7 














Within the week 49 18.0 
Within the month 22 8.3 
More than a month 18 6.8 
Total   270 100.0 
This shows that majority of patients have never reported ADR, while some that has reported 
stated that they never got feedbacks regarding the reported ADR. This can be attributed to lack 
of knowledge and awareness on how to report ADR and the importance of reporting it, while 





• Question 16: 
Table 14: Level of awareness about reporting ADR 
 Frequency Percent 
Low awareness (<= 2.00) 162 60.0 
High awareness (3.00+) 108 40.0 
Total 270 100.0 
Table 14 presents a classification of the respondents’ level of awareness based on their 
responses to questions on whether they have ever experienced an ADR, know how to report an 
ADR when they notice one, have ever reported an ADR, or whether they were aware of the 
SMS short code for reporting ADR. From a total obtainable score of 4 points, patients who 
scored 2 points and below were rated as having low level of awareness while those with 3 
points and above were rated as having high awareness.  
The result showed that most of the respondents (60.0%) had low awareness of ADR reporting 
whereas 40% had high level of awareness (Figure 7). Therefore, most patients do not know 
there is an SMS code that can be used to report any experience ADR directly to NPC. This 
established poor performance of the regulatory agency in publicising importance of reporting 
ADR and the basic reporting methods that can help patients report more at the comfort of their 
home while generating more ADR reports for the country to promote drug safety practice. 
 
 
Figure 7: Level of patients’ awareness 
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• Question 17: 
• Table 15: Reasons for not reporting ADR 
Reasons for not reporting ADR 
Yes No 
n % n % 
Adverse reaction may not be serious 71 26.3 199 73.7 
Adverse reaction resolved on it is own 51 18.9 219 81.1 
Do not know how to report such reactions 147 54.4 123 45.6 
Do not know the importance of reporting adverse drug reactions 133 49.3 137 50.7 
Unsure if adverse drug reaction is related to the drug(s) used 108 40.0 162 60.0 
Table 15 shows the reasons why patients chose not to report ADRs.  Of all the respondents, an 
overwhelming majority stated they do not know how to report ADRs (54.4%), followed by 
respondents that stated they do not know the importance of reporting ADRs (49.3%), while 
being unsure if adverse drug reaction was related to the drug(s) used (40.0%). Other reasons 
included thinking that the adverse reaction may not be serious (26.3%) and having the adverse 
reaction resolving on it is own (18.9%). 
The result depicts a broad response that indicates patients are not actively engaged and 
educated on the importance of reporting ADR. 
4.3.3. Direct Patient Reporting Improvement 
• Question 18: 
Table 16: Preferred method for reporting ADR 
 Frequency Percent 
Reporting directly to HCPs 169 62.6 
Direct Phone call or text message to National 
Pharmacovigilance Centre (NPC) 
61 22.6 
Online, mobile/web application 29 10.7 
Physically Filling a reporting form 10 3.7 
Never reported before 1 .4 
Total 270 100.0 
Table 16 presents patients’ preferred methods for reporting ADR. The findings showed that the 
most preferred method was to report directly to HCPs (62.6%). Other preferred methods 
included direct phone call or text message to National Pharmacovigilance Centre (NPC) 




This depicts that irrespective of direct patient reporting to NPC, overwhelming majority of the 
patients still prefer to report to their HCPs rather than directly to NPC. This is because they 
believe they will get immediate feedback from their HCPs. 
 
• Question 19: 
This section presents the proposed recommendation for the respondents to choose from by 
agreeing or disagreeing to the provided options. 
Table 17: Recommendation Towards Patient Reporting 
 
Strongly 
Disagree Disagree Neutral Agree 
Strongly 
Agree 
n % n % n % n % n % 
Increase awareness about patients reporting ADRs 
through local news, social media, and NGOs 
0 .0 3 1.1 10 3.7 41 15.2 216 80.0 
NPC and HCPs should relate feedback to patients for 
every reported ADRs 
0 .0 4 1.5 18 6.7 80 29.6 168 62.2 
Reporting process should be made easier and more 
accessible 
1 .4 1 .4 14 5.2 32 11.9 222 82.2 
Table 17 shows the distribution of respondents on recommendation towards direct patient 
reporting of ADR. Interestingly, an overwhelming majority of respondents agreed (strongly 
agree + agree) to all the proposed recommendations. 
95.2% agreed that there should be increased awareness about patients reporting ADRs through 
local news, social media, and NGOs.  
91.8% agreed that NPC and HCPs should relate feedback to patients for every reported ADRs, 
and 94.1% agreed that reporting process should be made easier and more accessible. 
This established that the proposed recommendation can help resolve underreporting issues, 
since patients can add value to pharmacovigilance structure by providing a more detailed 
reports with useful information which can help generate potential signals. 
 
4.4. Test of Hypotheses 
▪ Hypothesis One: There is no significant association between awareness on ADR 
and identification of ADR 
The first hypothesis asked if there was no significant association between awareness on ADR 
and the identification of ADR in practice. This association was tested using Chi-square test of 
association at 0.05 level of significance.   
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Table 18: Chi-square test of association between level of awareness and observed case of ADR in practice 
 
Low awareness (<= 2.00) High awareness (3.00+)  
M sd n % M sd n % Statistics 
No .3 .65 22 91.7 4.0 .00 2 8.3 Chi-sq = 5.67 
Yes 1.0 .82 75 67.6 3.8 .40 36 32.4 df = 1 
Total .8 .83 97 71.9 3.8 .39 38 28.1 p = 0.017 
The result showed that there was a statistically significant association between the 
professionals’ awareness of ADR and their observance of ADR cases in their practice (χ2 = 
5.67; p < 0.05), this implies that those who had high awareness tended to have high more 
number of cases observed. Based on the above, the H0 that there is no significant association 
between awareness on ADR and identification of ADR is rejected in favour of the H1 that there 






▪ Hypothesis Two: There is no significant association between patients’ source of 
knowledge on ADR and their ability to identify and report any experienced ADR. 
The second hypothesis asked if there was no significant association between patients’ source 
of knowledge on ADR and their ability to identify and report experienced ADR. This 




Table 19: Chi-square test of association between source of information about ADR and experience of ADR 
Which of the following sources did you obtain 
information about ADR? 
Have you ever experienced an adverse drug 
reaction? 
 
I do not 
know No Yes Total 
Statistics 
n % n % n % n % 
HCPs (doctors, nurses, pharmacist) 5 25.0 19 24.1 47 27.5 71 26.3 LR = 
13.37 
I do not know what adverse drug reaction is 5 25.0 8 10.1 4 2.3 17 6.3 df = 5 
Internet 1 5.0 21 26.6 50 29.2 72 26.7 p = 0.02 
Patient information leaflet from the drug 3 15.0 24 30.4 51 29.8 78 28.9  
Relative/Friend 6 30.0 5 6.3 15 8.8 26 9.6  
Television/Radio 0 .0 2 2.5 4 2.3 6 2.2  
Total 20 100.0 79 100.0 171 100.0 270 100.0  
LR = Likelihood ratio was used as the assumptions for the use of Chi-square test of association 
were violated. 
The result showed that there was a statistically significant association between the source of 
information and experience of adverse drug reaction (LR = 13.37; p < 0.05), which implies that 
patients that are well aware and informed about ADR can easily identify when a reaction is 
side effect or ADR through their source of knowledge.  Based on the above, we reject the H0 
that there was no significant association between patients’ source of knowledge on ADR and 
their ability to identify and report any experienced ADR in favour of the H1 that there is a 
significant association between patients’ source of information about ADR and their ability to 
identify and report any experienced ADR. 
 
        Patients response on the ability of how to identify and report experienced ADR 
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▪ Hypothesis Three: Perception of HCPs has no impact on direct patient reporting of 
ADR in Lagos State Tertiary Hospitals. 
The third hypothesis asked if Perception of HCPs has no impact on direct patient reporting of 
ADR in Lagos state tertiary hospitals. The association was tested using Chi-square test of 
association at 0.05 level of significance. 
Table 20: Chi-square test of association between perception of HCPs and direct patient reporting of ADR in 
Lagos State tertiary hospitals 
Do you think 
patients can write 




Do you encourage direct patient 
reporting of ADRs rather than through 
their HCPs? 
 
No Yes Total Statistic 
n % n % n % 
Yes 8 42.1 11 57.9 19 100.0 Chi-sq. = 6.44 
No 83 71.6 33 28.4 116 100.0 df = 1 
       p = 0.01 
 
The result showed a significant association between perception of HCPs and it is impact on 
direct patient reporting of ADR in Lagos State tertiary hospitals (Chi-sq. = 7.35; p < 0.05). 
patients who were not discouraged from reporting tended to make more reports of ADR than 
those who were discouraged. Which implies that patients who seek the opinion of their HCPs 
before making a report directly will end up not using the direct patient reporting channel. Based 
on the above, the H0 that Perception of HCPs has no impact on direct patient reporting of ADR 
in Lagos state tertiary hospitals is rejected in favour of the H1 that Perception of HCPs has an 
impact on direct patient reporting of ADR in Lagos state tertiary hospitals. 
 
4.5. Sociodemographic Factors and Level of Awareness 
This section assesses the relationship between sociodemographic factors and level of awareness 
among the patients.  
 
Table21: Test of association between sociodemographic factors and level of awareness 
 
Low awareness High awareness  
M sd n % M sd n % Statistics 
1. Gender Female 1.0 .82 73 45.1 3.1 .29 56 51.9 χ2 = 1.20 
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Male 1.1 .82 89 54.9 3.1 .27 52 48.1 df = 1 
Total 1.0 .82 162 100.0 3.1 .28 108 100.0 p = 0.27 
2. Age 18 - 30 years 1.0 .79 101 62.3 3.1 .30 62 57.4 LR = 6.06 
31 - 40 years 1.1 .87 43 26.5 3.0 .20 26 24.1 df = 4 
41 - 50 years 1.0 .85 15 9.3 3.0 .00 12 11.1 p = 0.20 
51 - 60 years 1.0 1.41 2 1.2 3.3 .49 7 6.5  
61 and above 2.0 . 1 .6 3.0 . 1 .9  
Total 1.0 .82 162 100.0 3.1 .28 108 100.0  
3. What is your 
highest level of 
education? 
Postgraduate 1.1 .83 107 66.0 3.1 .29 66 61.1 χ2 = 1.24 
Secondary education .5 .82 11 6.8 3.2 .41 6 5.6 df = 2 
Undergraduate 1.1 .77 44 27.2 3.1 .23 36 33.3 p = 0.54 
Total 1.0 .82 162 100.0 3.1 .28 108 100.0  
4. Which of these 
categories do you 
belong to? 
Academic Professionals 1.0 .65 15 9.3 3.0 .00 6 5.6 χ2 = 2.33 
Corporate/Office Worker 1.2 .81 58 35.8 3.1 .23 38 35.2 df = 4 
Self Employed 1.0 .85 47 29.0 3.2 .37 31 28.7 p = 0.68 
Students .9 .85 35 21.6 3.1 .28 25 23.1  
Unemployed 1.4 .79 7 4.3 3.0 .00 8 7.4  
Total 1.0 .82 162 100.0 3.1 .28 108 100.0  
 
The result showed that there was no significant association between the patients’ level of 
awareness and their gender (χ2 = 1.20; p > 0.05); age (χ2 = 6.06; p > 0.05); highest level of 
education (χ2 = 1.24; p > 0.05); and their occupational category (χ2 = 2.33; p > 0.05). This 
implies that patients’ characteristics (age, level of education and their occupational category) 
do not differ in their perception towards ADR, neither does it influence their decision to make 











4.6. Qualitative ANALYSIS  
4.6.1. Demographic Information 
 
Respondent Characteristics 
Sample size (n=6) 
Frequency 
• Gender  
                  Male 2 
                 Female 4 
• Experience Level (Years)  
                   10  1 
                 > 10 5 
• Role in the Hospital  
   Medical Doctor 2 
               Pharmacist 2 
               Nurse 2 
 
4.6.2. Themes Formation 
Phone Interview was conducted with 6 highly experienced HCPs from different tertiary 
hospitals in Lagos state Nigeria, to explore their perceptions on ADR assessment and reporting 
process, their perceptions about direct patient reporting, and also the challenges they face in 
the ADR practice. An abbreviated code was given to any class or theme recognized, and the 
purpose behind this is to connect topics in the obtained information and draw conclusions. 
Based on the respondents' similar qualitative opinions, five key themes were formed from the 
conducted interview and they will be discussed below alongside the response of the 
participants. The analysed result from the telephone interview with highly experienced HCPs 
helped to blend overlap with the survey questions and establish a meaningful conclusion and a 




4.6.3. Themes Discussion 
The five identified key themes are discussed in this section and each of the thematic discussion 
contained some transcribed quotes from the participants which were used to support the theme 
discussion. The participants were numbered based on their role in the hospitals for instance, 
participants 1 and 2 are medical doctors, 3 and 4 are Pharmacists, while 5 and 6 are Nurses. 
4.6.4. Theme 1 - Awareness/Knowledge on assessment and reporting of ADR 
In the conducted interviews, this theme was constantly talked about and all the respondents 
demonstrated knowledge of pharmacovigilance and as well as the importance of ADR 
reporting.  When respondents were asked to elaborate on their knowledge on ADR practice, 
convincing responses that solidified their awareness claim were obtained. They were all able 
to identify the regulatory body in charge of handling ADR reports, although only 50% of them 
correctly identified the location of the National pharmacovigilance centre operating in their 
geopolitical zone.  When asked if they are “aware of any form of casualty assessment of ADRs 
performed in Nigeria”? 80% stated that they have not heard of it before while 20% established 
that they have personal knowledge about it and they know a few of the algorithms used to 
perform ADR assessment. 
Furthermore, when asked if they “perform ADR assessment before reporting it and how is the 
assessment performed to identify if reaction is an ADR”? They were all able to demonstrate a 
great level of understanding on the importance of assessing ADR before reporting it. They all 
perform an assessment when a patient reports a reaction to them before concluding if it is an 
ADR or not. All the respondent described a common routine for assessing ADR when patients 
report to them; 80% go through patients’ history to know if they have underlining health issues 
that can trigger effects, ask several questions to know if the patients followed advised drug 
usage routine and use patients’ judgements and complain to decide, while 20% perform 
examination on patients and ask several questions to ascertain it is an ADR. Below are some 
of the response in the succeeding quote; 
Participant 2 (17 years’ experience) – “Although my hospital presently does not have any 
standard procedure/mechanism for such practice. However, I personally go through the drug 
leaflet to ensure the patient complains is not one of the stated side effects of the drugs, and if it 
is not, I do some examination, some cases take pictures if patients do not mind, and ask them 
questions so I can make a formal ADR report using the yellow form”. 
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4.6.5. Theme 2 - Familiarity with ADR reporting methods 
All interviewed participants demonstrated familiarity with the usage of ADR forms/ yellow 
forms, unfortunately, they are all unaware of the electronic reporting form available on the 
NAFDAC website and the SMS code introduced by NPC despite their years of experience and 
practice. Furthermore, only 50% was aware of the operating NPC in their geographical zone, 
while other respondents established that they have no idea where it is suited nor know if the 
centre is active.  
 In response to the question “what form of ADR reporting are you conversant with?” A similar 
response was obtained from all the participants explaining they are only aware of ADR forms 
and it is not easily available in their various tertiary hospitals. 
Participant 2 (17 years’ experience) – I'm only aware of the ADR form which I started using 
during my internship as a young doctor and I am still using it now, although it is not always 
accessible most times when we need it and I am guessing the e-reporting and SMS code is a 
modern thing and it has not been fully introduced to we HCPs….” 
The truthful opinion from all the respondents about their unawareness of the other 2 methods 
of reporting ADR indicated the situation may be peculiar to a significant number of HCPs in 
Nigeria. They do not have sufficient knowledge on the awareness of the other two methods and 
hence they don’t make any report if the form is not available. 
4.6.6. Theme 3 - Prevalence of ADR cases 
The respondents were asked, “How often do you observe ADR cases in your practice within 
the last 12 months”? The respondent all established that they frequently observe ADR in their 
practice but they sometimes do not report some of the cases they observe because they are not 
serious, unusual, or life-threatening. It was deduced that medical doctors and nurses experience 
more ADR cases in their practice because patients experiencing ADR usually go to their 
doctors or nurses rather than going to the pharmacists in the hospital. The doctors and nurses 
observe an average of 18 ADRs over the last 12 months of practice while the pharmacists 
observe an average of 7 cases over the same period. The pharmacists highlighted that reverse 
is the case in non-hospital settings as some of their colleagues that work in pharmacies tend to 
experience more ADR cases because of how easy it is for patients to purchase drugs without a 
prescription in pharmacies and they even tend to offer them treatment to any lodge complain 
rather than advising them to go see a doctor.  
Additionally, based on the question and the response of the participants, the researcher was 
propelled to come up with the following question “Do you get feedback or updates concerning 
67 
 
the previously reported cases”?  80% established that they never get any feedback or update 
concerning previously reported ADR cases, while 20% established they get feedbacks mostly 
from pharmaceutical companies though it might take a while. 
4.6.7. Theme 4 - Views on patient reporting of ADR 
When asked if they are “aware that patients can report directly to NPC and what is their 
perception towards it?”. 80% said they are not aware that patients are allowed to report directly 
to NPC until the commencement of this interview, while 20% are aware. All respondents stated 
that based on their “views on the patient reporting practice” they do not support the idea of 
patient reporting directly to NPC and held a strong view against the idea because they believe 
patients can’t generate a valid and quality report like the HCPs. Therefore, they should not be 
allowed to report directly, rather their report should pass through the HCPs for screening before 
it is being sent to NPC.  
Participants 3 (12 years’ experience) – “I don’t know that patient can report directly but 
since there is a system in place for that, the report should pass through their HCPs before the 
regulatory bodies because patients will only be able to describe how they feel but they might 
not be able to write down the valuable parameters needed to complete an ADR reporting, also 
most of them might fill the report halfway due to lack of knowledge or their busy schedule”. 
But when participants 2 and 3 were inquired about direct patients reporting and their 
perspective towards it, their responses provided a sound insight because they both are aware of 
the practice and they highlighted positive benefit is the practice has brought. But despite their 
positive view about direct patient reporting, they still believe patients can’t generate a valid 
report like the HCPs therefore the reporting process should be channelled through their 
physicians. 
However, 50% of the participants highlighted that some benefit can come out of patients 
reporting if they are properly educated and guided because they have unique experiences and 
perspective. “having a channel that encourages patient reporting will help achieve 
spontaneous ADR reporting because it will reduce the burden on HCPs and a combination of 
both patients and HCPs report will help generate more complete ADR report in the country if 
it is properly documented”. 
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4.6.8. Theme 5 - Common Challenges and Suggestions for Improvement of 
ADR Practice 
All the engaged respondents established that promoting effective assessment and reporting of 
ADR in Nigeria will be a difficult task because some common challenges and constraints occur 
in all Nigerian hospitals when it comes to ADR practice. When asked that “as a specialist what 
do you think is hindering effective ADRs reporting and assessment in Nigeria Hospitals, 
especially among HCPs, and what recommendation can you give in improving this”? They 
highlighted several bottlenecks including; lack of feedbacks from regulatory authorities, 
insufficient manpower, lack of awareness and knowledge on ADR practice, lack of expertise 
in the field, excess workload, insufficient staff and time, inaccessibility of ADR forms, 
cumbersome reporting process, and fear of been penalized for making a report. 
The respondents suggested improvements that can help NPC achieve spontaneous ADR 
reporting such as; more awareness, Training, seminars, and workshop should be introduced 
frequently to constantly educate and remind HCPs about ADRs practice in Nigeria. Feedbacks 
should be provided to inspire HCPs. Cumbersome of the reporting process should be 
minimized to the lowest level or removed totally if possible, availability and accessibility of 
reporting forms, Nigerian regulatory agency should actively engage patients to report more so 
we can generate more ADRs reports in the country.  
They demonstrated a strong attitude and intentions towards reducing mortality and morbidity 
caused by ADR to ensure patient safety and reduce it is economic burden. The respondents 
agreed with the proposed recommendations in the survey and they believe putting all the due 
actions in place can change the situation of ADR in Nigeria, although it might be challenging 
but it is possible if the right course of action is put in place and followed diligently.  
The response of the participants triggered another question which is “Do you think ADR 
assessment and reporting should be mandatory or voluntary”? All the participants established 
that assessment and reporting of ADR should a mandatory obligation of all HCPs. They 
highlighted that if it is mandatory they will all be forced to generate more reports and follow 
up on their patients regarding their medications. Additionally, they established that ADR 
reporting practice should be the duty of all HCPs and caregivers and not assume that it is the 





The finding and analysis presented above shows the level of awareness and knowledge of HCPs 
and patients on ADR practice in Lagos state tertiary hospitals. As discovered from this research 
there are several bottlenecks in Nigeria healthcare system that hinders effective practice of 
ADR assessment and reporting. HCPs clearly identified the basic steps needed to assess drug 
reactions, and the basic principles needed to make a report. The knowledge on establishing 
causal relationship between suspected drug and reaction is below average and this was because 
most of them have no prior knowledge about it nor is it a traditional routine in their hospitals. 
Additionally, their perception towards patient reporting indicated they have a negative believe 
about the success of patient's direct reporting of ADRs. HCPs believe that patients do not have 
sufficient knowledge required to generate quality and valid ADR report, therefore their 
reporting process is meant to be channelled through their healthcare providers to ascertain the 
report. 
Performance of patients on reporting ADR can be attributed majorly to their insufficient 
knowledge and awareness on the importance of ADR, it was established that their level of 
education or age doesn’t influences their decision to make a report. Therefore, the general 
public needs to be educated and actively engaged to strengthen their impacts. 
It was established that for both group of participants, insufficient knowledge and awareness is 
a major drawback on achieving effective ADR practice in Nigeria especially on the available 
reporting methods and knowing what ADR is. Although the regulatory agency in Nigeria 
(NAFDAC) has set in place the ideal models needed for reporting, however their performance 
towards awareness and publicity of adverse drug reaction was rated poorly and this in turn is a 
huge barrier in promoting drug safety practice and pharmacovigilance system in Nigeria. 
Fortunately, despite all the challenges, the HCPs exhibited a positive attitude towards achieving 
spontaneous ADR reporting if the appropriate resources and training are put in place, and 
majority of them are willing to update their knowledge personally to help reduce mortality and 
morbidity rate associated with ADRs and to invariably contribute to the overall 






CHAPTER 5: CONCLUSION AND RECOMMENDATION 
5.1. Answering The Four Main Research Questions 
Question 1: What are the assessment and reporting methods used by HCPs to identify and 
report ADRs in Lagos State tertiary hospitals? 
From the response obtained in the survey and interview conducted with highly experienced 
HCPs, it was established that majority of the respondent have an average knowledge of what 
ADR is, how to report it, and the appropriate channel to forward their report to. They 
demonstrated several methods they used to assess ADR before reporting it to the appropriate 
channel, and some of this methods include; patient examination, patients’ judgement and 
complaints, thorough questioning regarding the suspected drug and any other medication they 
are taking, however no one mentioned visual analogue scale which is more reliable to assess 
an ADR. Additionally, 80% of the respondents are not aware of what causality assessment is 
and the methods used to perform. They established that it is not a traditional routine in their 
hospitals, and they have no knowledge about it, also it was stated that is no awareness nor 
training on such practice to educate them and bring it to their notice. 
The responses obtained also established that out of the three basic ADR reporting methods 
available in Nigeria, the respondents are only familiar with ADR form/yellow form, this 
contribute significantly to the under reporting issues in the country because the respondents 
established that the form is not readily available and accessible and that impact their decision 
on making a report. 
Based on study, it is evident that there is a gap in the awareness and publicity of promoting 
causality assessment and the basic ADR reporting methods in Nigeria. This gap can be 
significantly associated to underreporting issues faced by the country despite the structured 
system put in place by NPC. The respondents of this study highly recommended consistent 
awareness and efficient information dissemination channel to help bridge the gap associated 
with lack of awareness and publicity on the assessment and reporting methods available in the 
country.  
Question 2: What are the perceptions of HCPs towards patient reporting ADRs in Lagos State 
tertiary hospitals? 
As established from the survey response and interview conducted, majority of the HCPs 
strongly oppose direct patient reporting and demonstrated a negative attitude towards it. 
Although a few of them are of the opinion that patients should be encouraged to make reports 
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because they believe their report can be a good source of ADR information since they are the 
ones experiencing the reactions. Despite the negative and positive views obtained from the 
HCPs regarding patients reporting, they are all of the opinion that patients do not have 
sufficient knowledge required to generate quality and valid ADR report, therefore their 
reporting process should be channelled through their healthcare providers to ascertain the 
report before going to NPC. This perception portrayed by HCPs establish that a cultural shift 
needs to transpire foster the cooperation of HCPs with the patient to autonomously report 
ADRs.  The analysis of their perception present a gap that needs to be filled to ensure that 
HCPs see the importance of direct patient reporting so they can actively promote and encourage 
their patients since a combination of both groups can help resolve underreporting issues and 
promote drug safety practice worldwide. 
Question 3: What is the level of awareness and knowledge of ADR among patients in Lagos 
state tertiary hospitals? 
The response obtained from patients’ survey established that the level of awareness among 
patients as regards ADR and it is basic reporting methods is very poor. Majority of the 
respondents has no knowledge about what ADR is and they have never reported experienced 
ADR because they do not know the importance of reporting such reactions and even how to 
report it. Furthermore, it was observed in the study that age, level of education, and 
occupational category doesn’t influence patients’ decision on reporting ADR, therefore the 
general public needs to be enlightened using all available medium and right source to create 
awareness and actively engage them to strengthened their impact. The research respondents 
suggested NPC should create more awareness on ADR, especially the SMS code created for 
direct patient reporting, and educate them more on the importance of reporting ADRs in other 
to bridge the barrier created due to lack of knowledge and awareness. Additionally, HCPs needs 
to educate their patients on their medication and possible risk associated with it so they can 
make a report when it is necessary since patients are a vital stakeholder in achieving 
spontaneous ADR reporting and establishing a viable pharmacovigilance system. 
Question 4: What are the challenges impacting ADR assessment and responsible for the slow 
involvement of tertiary hospitals in Lagos State? 
The response obtained from research respondents established that there are several bottlenecks 
and challenges impacting efficient ADR assessment and reporting in the aforementioned 
hospitals. This include- Insufficient staff, lack of knowledge on the assessment methods, lack 
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of resources, lack of feedback, time constraints, and rigorous/complex process. HCPs in tertiary 
hospitals are overwhelmed with workload due to the cadre of treatment they provide and influx 
of patients that uses the hospitals. They do not have enough time to perform ADR assessment 
and update their knowledge on the available methods for causality assessment. Additionally, 
most of these hospitals do not have an adverse drug event & therapeutic committee, and 
effective pharmacovigilance unit to help perform assessment on reported ADR cases and 
develop policies to manage drug use and administration. All the observed challenges cannot be 
neglected because they bear a burden on Nigeria healthcare system and they are significantly 
associated with the slow involvement of tertiary hospitals in Pharmacovigilance practice. 
5.2. Results from Primary and Secondary Data Comparison 
 According to research carried out by Avery et al in the UK concerning patients reporting, 
author established that patients are justified to report directly if they are educated on the process 
and more awareness is created. Also, a study by Inacio et al, suggested a public awareness 
program should be created for patients reporting. This awareness will enable patient have 
distinct reasons to report and denote an altruistic behaviour towards reporting. This 
recommendation aligns with the responses obtained from this research on direct patient 
reporting that there should be more awareness, and they should be actively engaged to report 
more because they have unique experiences and perspective that can provide a more detailed 
report with useful information which can help generate new potential signals and add value to 
pharmacovigilance structure. 
The regulatory agencies role and responsibility can’t be overemphasized on sensitising HCPs 
and the public as regards drug safety practices. A common theme generated from previous 
studies and this research is to encourage more awareness and dedicate adequate resources to 
improve ADR practice globally. The general factors such as lack of knowledge/awareness, 
insufficient resources, poor ADR recognition, cumbersome of reporting process etc. associated 
with underreporting in other countries remains the same to a great extent as observed from this 
study and other studies conducted in Nigeria.  
Additionally, results obtained on perceptions of HCPs towards direct patient reporting aligned 
with the outcome of similar research conducted in Malaysia by Alshakka et al, and in UK by 
Krska which established that HCPs are pessimistic about the success of direct patient's 
reporting of ADRs. About 70% of HCPs respondents in this study are not aware that patients 
can report directly, while 98% believe that patients do not have sufficient knowledge regarding 
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their medicines and hazards, therefore they can’t produce quality information on ADRs nor 
generate a valid report. 
5.3. Research Contributions and Limitations 
Majority of previously conducted research on ADR showed gaps in tertiary hospitals; most 
studies were majorly focused on ADR reporting and a group of HCPs in Nigeria hospitals, but 
this research compared the major stakeholders in achieving spontaneous ADR reporting. It 
focused on tertiary hospitals and involved ADR assessment with several HCPs (Doctors, 
Nurses, Pharmacists) and patients in one study. Furthermore, no study in Nigeria has explored 
and evaluated perceptions of HCPs towards direct patient reporting, and the level of 
knowledge/awareness of tertiary hospitals patients regarding ADR and available reporting 
methods for patients in Nigeria.  Based on the response obtained from 411 participants which 
was generated from both survey questionnaires and phone interviews that cut across all 
categories of tertiary hospitals in Lagos state Nigeria, despite the limited time and the 
unforeseen pandemic situation in the country. The findings from this research will help 
encourage direct patient reporting, and go a long way to help contribute to patients’ awareness 
and educate them on ADRs and the basic reporting methods available within their reach 
(especially the SMS short code) since most studies exclude them and rather focus on HCPs.  
This research will also help ensure HCPs are aware of benefit of direct patient reporting and 
improve their ADR practice to help reduce ADR burden faced by the country. It will provide 
them with useful insights into causality assessment of ADR, and basic ADR reporting methods 
especially the SMS code which is established on the NPC website but it is unknown to both 
HCPs and patients. 
The main limitation of the study was slow response from HCP participants for the survey, and 
accessibility to reach the interviewees due to their busy schedule as regarding the high number 
of covid-19 pandemic cases in the country. Some of the target participants called in advance to 
cancel the interview due to their busy schedule which led to a relatively small number of 
participants for the interview. Additionally, some of the participants proved hesitant to fully 
disclose their ADR practice and some level of accuracy to recall details, while some were also 
in a hurry to attend to patients which was reflected from the responses they provided in the 
transcripts. This led to interruptions during the interviews and the inability to deeply explore 
their perceptions as earlier planned by the researcher which could impact the interpretation of 
the result obtained. Finally, due to unforeseen pandemic and global lock down, the researcher 
could not get hold of submitted ADR reports to evaluate their completeness and perform 
74 
 
causality assessment on them to establish with certainty the potential causal relationship 
between drugs and ADR. 
5.4. Recommendations for Practice 
From research findings, it is evident that there is need to address lack of knowledge and 
awareness among HCPs as regards causality assessment of ADR and basic reporting methods 
available in the country. The regulatory agency needs to create more awareness and publicity 
on ADR practice in Nigeria, because despite the valuable resources available on their website, 
most of the respondents are still unaware of these basic resources or even utilised them. 
Additionally, since the involvement of tertiary hospitals is still quite slow in implementation 
of most of the objectives stated in the pharmacovigilance policy. Active pharmacovigilance 
units should be positioned there to assess and monitor ADR cases regularly, especially 
causality assessment and make it a traditional routine in the hospital since most ADR evidence 
and cases arise from these settings due to high risk associated with their treatments. The 
bottlenecks and cumbersomeness of the process should be eliminated, feedbacks should be 
constantly provided to HCPs to encourage them to be actively involved in the assessment and 
reporting process, and strengthened pharmacovigilance practice in the country. Also the 
orientation programs of newly employed HCPs and undergraduate modules should include 
curriculum that focus on ADR assessment, importance and basic principles of reporting ADR, 
authorities in charge of handling ADR reports etc. while frequent training and seminars should 
be organised as well to update their knowledge on pharmacovigilance and drug safety practice.  
HCPs need to adopt new parameters to proactively monitor and assess ADR continuously and 
integrates patient’s safety as core value and practice, therefore they need to encourage and 
promote direct patients reporting by ensuring patients are aware of the risk their medications 
and a suitable course of action to take in case they occur. A culture of notification to enable 
smooth flow of information dissemination and promote patient safety needs to be deployed 
among HCPs. 
Finally, NPC needs to establish a solid foundation to educate patients on the importance of 
reporting ADR and basic reporting methods available to them to help promote drug safety 
practice. The SMS code proved to be user-friendly but it is vital to address the issue of relating 
feedbacks to patients through that same channel to encourage them to use the feature more and 
be actively involved.  
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5.5. Recommendation for Future Research 
Future research should be conducted on a larger group of participants and extended to tertiary 
hospitals in other parts of the country to explore in-depth perceptions. Future study should be 
conducted over a long period of time to carefully assess in-hospital incidence of ADRs to find 
out culprit medications, more information on drug exposure, and poor ADR recognition.  
Furthermore, this research only scratched the surface area of assessment and showed gaps in 
the knowledge of causality assessment performed in Nigeria. Future research should consider 
going deep into this topic and subject reported ADR cases into causality assessment to enable 
rapid detection of potential signals related to drug use, help identify rare and serious ADRs, 
and propose how the practice can be improved. Incompleteness of reports should also be 
assessed on submitted ADR reports to identify variances in quality of reported data, prevalence 
of ADR, and all other relevant missing data of submitted reported to NPC which hinders 
complete evaluation of submitted reports for drug causality.  
Additionally, Future research should consider assessing ADRs related to herbal medicines 
which is broadly used by Nigerian population especially in the rural area of the country. 
5.6. Conclusion and Reflection 
The entire process of the research was rigorous, insightful and exciting. Findings from this 
research helped developed researcher’s knowledge on ADR and gave her deeper insights into 
challenges faced by both HCPs and patients as regard ADR. The study also helped filling gaps 
on HCPs and patients’ perspectives on ADR, and also gave answers to several questions the 
researcher wanted to understand especially perception of HCPs towards patient reporting as it 
is an area that has not been explored in Nigeria. 
Nigeria is earmarked as a fast-developing country and a leading nation in the future, therefore 
the country has to be established on all aspect especially the healthcare system starting with it 
is HCPs and regulatory agency. However, from reviewed literature and findings obtained from 
the study, it can be deduced that global underreporting issues are significantly associated with 
lack of knowledge and adequate resources dedicated to identify, assess, monitor, and report 
potential ADRs effectively. The reporting and assessing medium in Nigeria tertiary hospitals 
is inadequately efficient and somehow being underutilized by Nigerians including it is HCPs 
and healthcare providers due to lack of dedicated resources to the process, and persistent focus 
on knowledge acquisition instead of it is implementation and feasibility. The resulting effect 
of this act is the burden of ADR faced by the country and inability to achieve required ADR 
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reported cases despite the high mortality and morbidity rate associated with ADR cases in the 
country.  
Despite the several bottlenecks and loopholes which hinders ability to spontaneously report 
ADR and identify rare/serious ADRs that may occur after drugs are marketed. HCPs are willing 
to improve drug safety practices and pharmacovigilance system in Nigeria by acknowledging 
that ADR reporting law should be amended to a mandatory practice for all HCPs in order to 
incorporate sense of ownership, resolve underreporting issues, and variance in the quality of 
ADR report submitted.  
It is essential that the Nigerian government, corporate bodies, citizens and all other stakeholders 
be aware of this collective goal and play their roles diligently towards achieving it. Patients 
should be educated, encouraged and actively involved on ADR reporting because they have 
the potential to add value to generated reports by providing a more detailed reports which can 
help detect likely causality and impact on patients’ lives. Adequate resources and awareness 
should be dedicated to ADR practice, seminars, training and workshops should be frequently 
provided for HCPs in Nigeria. This will invariably contribute to overall pharmacovigilance 
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